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Abstract
Wound healing is an intricate biological process requiring the appropriate balance of matrix and
growth factors. Apart from causing physical deformity, adult wound healing results in the formation
of scar tissue, which can hinder functionality and mobility due to excessive wound contraction.
Wound care is a significant clinical problem for chronic wounds (eg. diabetic ulcers), acute injuries
(eg. burns) and in elective surgeries (eg. scar revision). With an overall annual cost of $16 - 22
billion, wounds severely burden the U.S. healthcare system, and are the fastest growing area in the
medical sector. Thus, the goal of promoting faster healing with "scar-less" wound resolution remains
unchanged.
Skin substitutes, such as IntegraT M and AllodermTM, have been developed to treat chronic
wounds and extensive burns. However, they are susceptible to infection, prone to shearing and
exhibit poor biodegradation. These limitations could potentially be overcome by expediting blood
vessel growth which would promote a more rapid integration of the skin substitute with the sur-
rounding tissue. Experimental evidence also suggests that down-regulating inflammatory cells and
up-regulating stem cells and progenitors cells would yield less scar formation. But, these therapies
require an expensive isolation and culturing process from the patient's bone marrow. Additional
risks include immune rejection concerns, limited shelf-life and stringent storage requirements.
To meet this need, a stem cell-attractant and inflammatory cell-repellant chemokine, Stromal
cell Derived Factor-1 (SDF-1) was incorporated into a highly porous collagen-glycosamino-glycan
(GAG) matrix (skin substitute). The hypothesis is that this enhanced skin substitute would expedite
wound healing and decrease abnormal scarring by a mechanism where stem cells from the patient's
circulation would be attracted to the wound site while inflammatory cells would be repelled. The
purpose of this study is, thus, to elucidate the potential of SDF-1 to improve skin wound healing.
Experimental results demonstrated that topical application of SDF-1 induced changes in wound-
healing kinetics (contraction and re-epithelialization) compared to spontaneous healing in un-treated
wounds (Control group). A reproducible dorsal full-thickness excision wound model in wild-type
mice was used and wound repair was assessed both macroscopically and microscopically. The SDF-1
treated group demonstrated the fastest rates of wound closure and cell proliferation as compared
to the Control group, with re-epithelialization occurring more rapidly by 36%. Qualitatively, the
amount of early cell infiltrate in the SDF-1 group was also significantly less when compared to
the Control group, which is indicative of a decreased inflammatory response. In addition, wounds
treated with SDF-1 exhibited reduced wound contraction initially during the healing process.
These experimental results demonstrated a synergy between SDF-1 and the scaffold that pro-
moted faster wound closure and reduced contraction. Thus, the SDF-1 treated-dermal matrix may
be a new tool to stimulate wound closure and quality tissue formation in acute and chronic wounds.
Other potential applications include tissues that exhibit poor regeneration after injury, such as
cornea, spinal cord and heart. The development of such solutions would, therefore, be of significant
benefit to human health.
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Chapter 1
Introduction
1.1 Background and Significance
Even with the evolution of wound care, the goal of promoting faster and better wound healing
remains unchanged. Apart from causing deformity and death, wounds are a severe burden on the
U.S. healthcare system with an annual overall cost of $16 - 22 billion.[1 ] With an annual growth rate
of 10%, it is the fastest growing area in the medical sector per Espicom Business Intelligence. [2] The
Centers for Disease Control and Prevention (CDC) estimated that 27 million surgical procedures
are performed annually.[3 1 This includes emergency procedures, like burns, and elective procedures,
such as scar revision.
As the U.S. population ages, the incidence of chronic wounds is projected to increase to 5 million
a year, costing $4 billion in 2004 per Taglich Brothers Inc.[ 4] Diabetes mellitus contributes to 50%
of all lower extremity amputations in the United States with approximately 15% of all patients
developing foot ulceration with infection.[5],[6 ] Thus, foot ulcers are the leading cause for hospital-
ization in diabetic patients with an annual health care cost greater than $1 billion.17 1 Wound care
and management of pressure sores and venous stasis ulcers are also very expensive. Even though
most pressure and venous ulcers do not require amputation, they result in reduced quality of life for
the patient (Figure 1-1, (a)).
(a) Pressure sore on Buttock (b) Scarring in Burn Patient
Figure 1-1: Clinical Problems
With an annual rate of approximately 600,000 wounds in the United States, the average cost
of treating venous leg ulcers is estimated at $2400 per month.[8] Pressure ulcers have a prevalence
ranging from 8.8% in institutionalized patients to 14.8% in patients in acute care facilities, with an
average cost of treatment of up to $70, 000.[81 The number of burn victims stands at 2.4 million per
year and is expected to grow by 5% every year (Figure 1-1, (b)).
Around 30% of these injuries are treated by medical professionals and of those hospitalized,
20,000 have major burns involving at least 25% of their total body surface area, and 12,000 of
these patients die.[9] Burns are one of the most expensive catastrophic injuries to treat and require a
multi-disciplinary team of medical professionals. For example, a burn involving 30% of the total body
surface area costs as much as $200,000 in initial hospitalization and physician fees. Furthermore,
undesirable scars result in as many as 50% of cases with deep burns (www.burnsurgery.org), which
results in a reduced quality of life due to a loss of mobility and functionality. Burn patients often
undergo repeated reconstructive surgeries to ameliorate the scars, as well as extensive rehabilitation.
Severe burns also frequently lead to post-traumatic stress syndrome and long-term psychological
damage due to physical disfigurement.
1.2 Skin and the Physiology of Wound Healing
1.2.1 Anatomy of Skin
At 12 - 15% of the total body weight and with a surface area of 25 square feet, the skin is the largest
organ in the body. It maintains homeostasis by providing a protective barrier against the outside
elements and microorganisms, by regulating the internal body temperature through sweat-producing
glands and dilation of blood vessels, and by preventing excessive water and extracellular fluid loss.
Other functions of the skin include synthesis of vitamins and hormones, such as Vitamin D, and
sensory reception via specialized nerve receptors for touch, temperature, pain and pressure.
Figure 1-2: Anatomy of Skin and Wound
Normal skin consists of the following distinct primary layers (Figure 1-2):
1. Epidermis - The epidermis is the outermost layer of the skin and is a transparent membrane
contiguous with the mucous membranes. Its primary function is to form a barrier to the
external environment against dehydration and the entry of microbes, such as viruses and
bacteria, into the body. Acidic secretions from the skin also help retard fungal growth. The
epidermis receives its nutrients from the dermis as it does not have any blood vessels. The
basic cell type of the epidermis is the keratinocyte, which contains an insoluble fibrous protein
called keratin. Keratin water-proofs the surface of the epidermis while giving it properties
of strength and flexibility. Keratin is also the major component of hair and nails. Thick
skin epidermis typically has 5 strata. The innermost layer of the epidermis (stratum basale)
comprises of basal cells and melanocytes. The melanocytes produce the pigment melanin and
store carotenoids, both of which are responsible for imparting color to the skin.[10 1 The melanin
also helps protect the skin from harmful ultraviolet radiation. Langerhans cells are also present
in the epidermis. These cells are dendritic cells that are responsible for alerting the immune
system of the presence of pathogens and foreign materials.111 ] The outer epithelial layer of
dead keratinocytes (stratum corneum) is replaced every 3 to 4 weeks by new epithelial cells
that are pushed up to the surface from the dermis. [12l
2. Dermis - The dermis is the layer beneath the epidermis and comprises the largest segment
of skin. Its primary function is to provide structural integrity to the skin and supply blood
and nutrients to the epidermis. The dermis has two layers that are closely associated. The
innermost layer (reticular layer) is made of a dense, criss-crossing, connective network of col-
lagen fibers. The basic material properties of skin are due to the collagen protein providing
it strength and structure, and elastin protein giving it flexibility.[13 ] Sensory receptors for
deep pressure (Pacinian corpuscles), sweat and oil producing glands, lymph vessels and hair
follicles are also present in the reticular layer. The outermost layer (papillary layer) has loose
connective tissue and connects to the epidermis via papillae (finger-like projections). These
papillae contain sensory touch receptors (Meissner's corpuscles), thermoreceptors and vessels
that nourish the epidermis. Collagen producing fibroblast cells are also present in the papillary
layer.[121
3. Hypodermis - The hypodermis layer or the subcutaneous tissue layer, lies beneath the dermis.
It primarily consists of adipose (fat) tissue and blood and lymph vessels. Adipose tissue aids
in conserving heat within the body, cushions the body against physical forces and gives the
body its shape and form.[14]
1.2.2 Classification of Skin Wounds: Acute versus Chronic
A wound is defined as a "disruption of the normal anatomic structure and function", per the Wound
Healing Society.[15] Wounds are typically categorized as being either acute or chronic.
In acute wounds, reparative healing progresses normally in an orderly and timely process.
Whereas, in chronic wounds the repair process has failed to ensue and result in closure of the
wound area. This is typical in non-healing wounds such as venous stasis ulcers, pressure sores and
diabetic ulcers. Large trauma areas with extensive tissue loss, such as third-degree burns, are also
at risk of developing in to chronic wounds.[15 ]
1.2.3 Types of Healing: Regeneration versus Repair
In superficial injuries and burns, the dermis is largely intact and enough epidermal cells remain
that can proliferate, stimulated by factors released by the dermis underneath. Therefore, complete
regeneration can occur spontaneously in four weeks or less.[1 3] Regeneration involves the gross
replacement and restoration of tissue mass with normal architecture and function.
In deep acute wounds, the epidermis is completely destroyed and the dermis is significantly
damaged (Figure 1-2). Thus, the healing process is reparative and not regenerative. Wound repair
involves the synthesis of scar tissue without restoration of the normal structure and function of the
tissue or organ.[1 31
The process occurs by either primary, secondary or tertiary intention which is described in
further detail below[1 6]:
1. Healing by primary intention - This process typically occurs in most surgical wounds
whose skin edges have been adequately brought together (apposed). These wounds types heal
rapidly and the resultant scar will depend on the skin type of the patient and the direction of
the scar in relation to Langer's lines (alignment of the collagen fibers within the dermis).[ 151
2. Healing by secondary intention - Wounds that are left open and heal by the natural wound
reparative process, by and large, heal by secondary intention. Wound types that undergo
healing by secondary intention include large wounds with extensive tissue loss following massive
trauma, such as third-degree burns. The wound phases of the wound reparative process are
more pronounced than in healing by primary intention resulting in severe wound contraction
and scar formation. [15 1
3. Healing by tertiary (delayed primary) intention - Wounds that are infected or have for-
eign material, cannot be closed surgically until the complications have been resolved. Healing
by tertiary intention can also be induced by surgical skin graft reconstruction in large open
wounds caused as a result of severe trauma. This is extremely important as failure to heal
within one month could result in a sub-acute state that may evolve into a chronic state if
healing by secondary intention is not achieved within three months.[1 5]
Primary or tertiary wound healing is preferred to secondary healing. This is because healing
by secondary intention involves a more severe wound reparative process of wound contraction and
scar formation, which may result in physical impairments of decreased functionality and abnormal
appearance.[1 3] Furthermore, deep injuries involving large surface areas do not heal spontaneously
and must be covered with full-thickness skin grafts, which are obtained from other healthy donor
areas of the body. In addition, life-threatening complications, associated with large open wounds of
greater than 20% area, can arise from systemic shock caused by excessive fluid loss[171 or due to the
onset of sepsis. [18 1
1.2.4 Physiology of Wound Repair Process
The process of skin wound healing by repair can be divided in to the following phases:
1. Inflammatory Phase (from time of injury to Day 4 post-injury) - The inflammatory phase
sets in within minutes of injury. First, blood supply to the wound site increases which leads to
aggregation of platelet cells and fibrin clot formation (hemostasis).11 9] The purpose of hemosta-
sis is to cease the bleeding and provide a temporary barrier to protect the underlying tissue
from the external environment and microbial invasion. In addition, blood-borne leukocytes
(neutrophils and monocytes) and macrophages enter the wound site to clear away any cellular
debris or foreign material. Gross macroscopic characteristics of the inflammatory phase include
reddening of the wound area and edema.[12J,[20J (Figure 1-3 and Figure 1-4)
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Figure 1-4: Clot Formation in Inflammatory Phase
2. Proliferative Phase (from Day 5 to Day 14 post-injury) - The proliferative phase involves the
initiation of repair of the epidermis and the dermis. Fibroblast cells and endothelial (vascular)
26
cells migrate in to the wound site and work in concert to fill in the wound area from the base
of the wound with a richly vascularized collagen and connective tissue dermal composite called
granulation tissue.[12 ] The granulation tissue is deposited in to the wound area in a disorganized
manner by the increased synthesis of fibrillar collagen and fibronectin. Simultaneously, the
wound contraction process is induced by growth factors such as TGF-01 wherein contractile
myofibroblast cells decrease the dermal gap by binding to the surrounding collagen network
using proteins such as integrins.[2 1],'22 ],[ 3]', 2 4] As the actin filaments in the myofibroblast cell
contract, the dermal edges of the wound are pulled together, while fibroblasts synthesize more
collagen to reinforce the wound area. A prolonged contraction process, which is common after
large and deep burns, can inhibit joint movement depending on the wound location.[ 2 5] ,12 6]
In addition, keratinocytes from the wound edges begin to migrate over the granulation tissue
to re-epithelialize the wound surface by forming a new epidermis. In the absence of a clean
and moist wound environment with healthy blood flow, the re-epithelialization process will not
progress normally and necrotic tissue (eschar) will develop, which would need to be debrided
before the normal healing process can resume.[ 12] The formation of eschar is very common in
burn injuries (Figure 1-5)
Figure 1-5: Proliferative Phase
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3. Maturation Phase (from Day 15 to months or years post-injury) - Once the myofibroblasts
commit apoptosis and the fibroblasts stop proliferating, the healed wound enters the matu-
ration phase. The granulation tissue continues to be remodeled and the epidermis matures.
The neo-epidermis may be distinguished from the epidermis of normal unwounded skin by a
"smoothened" appearance, which is caused due to lower densities of undulations (rete pegs). [271
The granulation tissue is eventually converted in to an avascular cutaneous scar composed pri-
marily of fibrous connective tissue produced by fibroblasts. The immature scar is typically
denser and thicker with a higher concentration of immature Type III collagen than in the
surrounding normal dermis.[2 8] Over time as the scar matures, the collagen type is mainly
replaced by a mature Type I collagen.[29] Rarely do skin appendages such as hair follicles and
sweat glands return and the normal architecture and functionality of the tissue is not fully
restored. [13] The tensile strength of the scar formed is, at best, 70% of the tensile strength of
normal unwounded skin. [3 0] Since the scar tissue is less elastic, it is vulnerable to further break-
down. In addition, fibrotic scar formation can result in complications such as an abnormal
appearance due to skin discoloration and excessive granulation tissue deposition (hypertrophic
scars and keloids), and impaired mobility and functionality.[2 0],[13 ] (Figure 1-6)
Blood Vessel
I
Re-epithelialized
Wound
Epidermis
M-- yofibrobl astf
C7 / r) -ý 
F i b r o b l a s t
Coll agen
Fiber Mac rphage
Figure 1-6: Maturation Phase
figure Courtesy: Sawdd2K.
Chapter 2
Current Treatment Methods For Skin
Wounds
2.1 Tissue-Engineered Skin: Role of Skin Substitutes
Tissue-engineered skin, also known as skin substitutes, refers to skin products consisting only of cells
or only of extracellular matrix materials, or to a combination of both. Their function is to aid the
healing process by providing the needed matrix, growth factors or cells.[3 1] The extent of damage
to the dermis has been directly correlated with an increased propensity to develop scarring. Skin
substitutes have been developed to promote regeneration of the dermis, such as IntegraTM (Integra
Life Sciences, Plainsboro, NJ) and AllodermT M (LifeCell Co., Branchburg, NJ). These dermal skin
substitutes are applied onto the cleaned wound bed and provide a support structure for blood vessels
and other cells to migrate and grow into. After 2 weeks, they are sufficiently vascularized to support
an epidermal skin graft, which is required to regenerate the epidermis. (Figure 2-1)
Figure 2-1: Use of Skin Substitutes for Deep Wounds
2.2 Role of Circulating Stem Cells
Data from literature suggest that during injury, bone marrow-derived stem cells and vascular pro-
genitor cells which are released into the circulation, can spontaneously migrate into the site of injury
and participate in the wound healing process.[3 2 1,[33] Experiments where isolated stem cells, such as
mesenchymal and hematopoietic stem cells, were directly injected into injuries have demonstrated
enhanced regeneration characterized by better functionality and decreased scar tissue.[3 4], [3 5 ],1[36 ],[3 7]
2.3 Role of Inflammatory Cells
The recruitment of blood-borne immunocompetent cells, such as T cells and B cells, into the wound
site is a major component of the local inflammatory response, which plays a key role in the formation
of granulation tissue and the initiation of the wound healing response. Increased levels of T cells
have also been associated with post-burn hypertrophic scar formation. [3 8 ]
Over 10 years ago, a new population of leukocytes called "fibrocytes", that entered the wound
at the same time as inflammatory leukocytes, was identified, which appear to emanate from the
stromal compartment of the bone marrow .[39] More recently, a significant increase in circulating
levels of fibrocytes was documented in burn patients.[40] Although these cells may contribute to
the wound healing process, there is evidence that these cells are also involved in fibrotic responses
including hypertrophic scars and keloids.[4 1] On the other hand, in established scars and keloids,
their presence (based on CD34 antigen expression) seems to correlate with locally decreased collagen
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synthesis activity.[4 2]
An intriguing fact is that the lack of an inflammatory response is not always detrimental, as
is the case in fetal wound healing. A hallmark of fetal wound healing is the lack of a significant
inflammatory response. The switch from scar-less fetal wound healing to wound healing leading to
scar formation, which is characteristic of adults, is thought to correlate with the development of the
immune system and the appearance of immunocompetent cells. [4 3] Depending on the wound size
and depth, fetal skin wounds heal scarlessly during periods of early skin differentiation; but this
ability is progressively lost in late periods of gestation.[4 4] Thus, the inability to fully regenerate
damaged tissues as the fetus progresses to later stages may also be due to other factors, such as the
lack of cues that were originally present during skin development which guide morphogenesis of the
tissue. The lack of progenitor cells with sufficient proliferative capacity to restore the tissue could
be yet another contributing factor.
2.4 Limitations of Current Treatment Methods
Although the existing dermal skin substitutes are tremendous advances in the treatment of severe
skin injuries, they lack intrinsic antimicrobial activity and are susceptible to infection due to slow
vascularization.[45 ] Infection increases the incidence of scarring.[4 6 ] Other complications, such as
shearing of the skin substitute from the wound bed due to inadequate angiogenesis and deposition
of non-degraded fibers in the wound bed due to poor biodegradation, have also been observed.[4 7]
Furthermore, skin substitutes do not inhibit long-term wound contraction.[4 5 ] These limitations
could potentially be overcome by expediting blood vessel growth into the skin substitute as active
blood vessels enable infection-fighting immune cells to enter and "monitor" the wound site. Blood
vessel growth is a rate-limiting process for the migration and proliferation of cells from the wound
bed. Therefore, faster blood vessel growth would promote a more rapid integration of the skin
substitute with the surrounding tissue, thus, reducing the risk of its shearing and avulsion from
the wound site. Faster vascularization of the skin substitute would decrease the time needed before
epidermal skin grafts can be applied onto the wound. This would result in faster wound healing
overall. Finally, faster wound healing is correlated with better appearance and less scarring of the
healed wound, based on VEGF antigen expression. [3 1] Thus, a strategy that speeds up blood vessel
growth may also reduce scar formation.
Stem cell-based therapies require an expensive process of isolating and culturing large numbers
of cells from the patient's bone marrow. Also, cell-based therapies are not easily amenable to
becoming off-the-shelf products due to immune rejection concerns, limited shelf life and stringent
storage requirements.
Chapter 3
Proposed Approach
3.1 Stromal cell Derived Factor-1 (SDF-1)
The proposed approach is to enhance commercially available skin substitutes by incorporating a
stem cell attractant peptide that promotes the homing-in and recruitment of circulating stem cells
and progenitor cells into the wound site while repelling inflammatory cells. A well characterized
full-thickness skin wound experimental model will be used in this study.
The selected peptide is Stromal cell Derived Factor-1 (SDF-1), which is also known as CXCL12.
SDF-1 is an 8 kD CXC chemokine known to bind receptor CXCR4. Binding of the receptor triggers
downstream signaling events inside the cell that eventually lead to cell migration towards the source
of SDF-1. SDF-1 is structurally grouped into two subfamilies, SDF-la and SDF-1f, with similar
activity. It is expressed during homeostasis in many organs, including adult bone marrow endothe-
lium and the stem cell rich endosteum region. Multiple stromal cell types such as bone forming
osteoblasts, adipocytes, fibroblasts and endothelial cells produce this chemokine. The human and
mouse chemokines are very similar.
Although its half-life in vivo is unknown, SDF-1 can be cleaved at the N-terminus and can be
degraded by a wide array of proteolytic enzymes.[4 8 ] Because cell migration is a process that occurs
over several days, SDF-1 must be delivered over an extended time course. Thus, the timing and
dosage of administration of exogenous SDF-1 may significantly affect the concentration of active
SDF-1, which may in turn lead to complex dynamics of attractant and repellent effects of the
chemokine on CXCR4 cells in the wound site.
SDF-1 is a stable peptide and can be incorporated during or after the manufacture of existing
FDA-approved (U.S. Food and Drug Administration) skin substitutes. Therefore, it would not
require any changes to their existing storage or handling requirements. With this approach, the
benefits of stem cell-induced regeneration can be leveraged in vivo without the need for a costly
cell-based product.
3.2 Role of SDF-1 in the Local Response to Injury
There is evidence in literature that increasing SDF-1 levels can be beneficial to wound healing.
Synthesis and expression of SDF-1 is regulated by hypoxia-inducible factor 1, and has been shown
to occur in skin and liver as a result of oxygen deprivation induced by injury or infection.[4 9] ,[50 1,[5 11
SDF-1 is part of an endogenous mechanism that recruits stem cells into damaged tissues.[52],[53],[54]
This was also seen in a study where injection of genetically modified cells that over express SDF-1 into
a model of myocardial infarction in mice showed increased stem cell recruitment into the damaged
heart area, greater left-ventricular mass and better cardiac function.[5 3] Another study involving the
administration of SDF-1 into diabetic wounds demonstrated enhanced endothelial progenitor cell
mobilization, homing, and wound closure.[5 5] In addition, transgenic mice that express higher levels
of SDF-1 exhibited accelerated closure rate of skin wounds.[5 6] An interesting and alternative theory
with regards to the role of SDF-1 in burn injury has been proposed recently where a study found
that blocking endogenous levels of SDF-1 resulted in increased re-epithelialization and decreased
eosinophil infiltration in second-degree dermal burn wounds 5 days post-wounding.[ 5 7l However,
since the healing process was not followed until complete wound closure occurred, it is unclear as to
what the long-term effects of blocking SDF-1 would be on burn injuries.
3.3 Role of SDF-1 in the Attraction of Stem Cells
Based on literature data, it has been observed that SDF-1 is chemotactic (attractant) for several
different types of cells, namely, Hematopoietic stem cells[5 8]'[5 9 ],[6 0 ]'[6 1], Endothelial progenitor
cells[ 62 ],[63 ],[6 4],[6 5],[6 6],[6 7 1, and Mesenchymal stem cells[6 8 ]'[6 9]. Endogenous SDF-1 also plays a
key role in the induction of blood vessel growth triggered by well-known angiogenic factors, such as
VEGF and bFGF.[6 7 ],[7 0l ,[7 1l (Figure 3-1)
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Figure 3-1: Role of SDF-1 in Attraction and Repulsion of Cells
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3.4 Role of SDF-1 in the Repulsion of Inflammatory Cells
Until recently, chemokines such as SDF-1 were thought only to have chemoattractant activity for
specific subpopulations of leukocytes. However, it was recently demonstrated that the effect of SDF-
1 is dose dependent. Specifically, while it is chemotactic for T cells at concentrations up to 100
nM, it repels CD4 and CD8 T cells at concentrations above 100 nM. This mechanistic property is
termed "fugetaxis" or "chemorepulsion". T cell fugetaxis was shown to be CXCR4-dependent but to
have a signal transduction pathway that was distinct from that for chemoattraction. T cell fugetaxis
was also shown to play a physiological role in the exit of mature T cells from the thymus and may
contribute to a novel mechanism by which HIV-1 and certain forms of cancer evade the immune
system.[7 2],[7 3],[7 4],[7 5 ] More recently, other chemokines, such as eotaxin-3, CXCR3 ligands, and
IL-8 were shown to act as chemorepellents for human monocytes, dendritic cells and neutrophils,
respectively.[7 6],[7 7 ],[78 1 Furthermore, recent studies have shown that high levels of SDF-1 production
by transplanted cells resulted in the survival of the allograft in diabetic mice, significant reductions
in their blood glucose levels and T cell infiltration into the transplanted tissue in contrast to control
group where the transplanted cells were rejected and the mice remained diabetic. [79] (Figure 3-1)
3.5 Hypothesis
The basis for this research topic is that exogenous SDF-1 can improve skin wound healing by al-
tering the dynamics of recruitment of CXCR4-expressing cells, including inflammatory cells (such
as lymphocytes), endothelial progenitor cells, and several other types of stem cells. Standardized
quantification of the main characteristics of wound healing, such as re-epithelialization, wound con-
traction, angiogenesis, cell proliferation and collagen deposition, is necessary to evaluate the effect
of SDF-1. The dosage and delivery time period of SDF-1 to the wound site is critical to ensure
attraction of stem cells and repulsion of inflammatory cells.
Chapter 4
Materials and Methods
4.1 Rationale for Design of Experiment
The basis for this study is to investigate the effect of exogenously applied SDF-1 on dermal wound
healing. This model uses a full-thickness excision wound in mice grafted with a Collagen-GAG
dermal scaffold. Wild-type C57BL/6 mice were used as they have been shown to have limited
regeneration and poor healing with scar formation.[80] Although there are significant anatomical
and physiological differences between rodent skin and human skin, the mouse model is a convenient
and commonly used animal model for studying dermal wound healing kinetics.[81]
The scaffold has two purposes: (a) it is a convenient delivery vehicle for SDF-1 in to the wound,
and (b) it has been shown to significantly reduce contraction when grafted in to skin defects in
rodents.[82 ] Since contraction accounts for more than 95% of the healing process in rodents as
compared to humans[13 1, the use of the scaffold may facilitate observation of important biological
events that could be relevant to human dermal wound healing. In contrast, humans heal less through
contraction and more through re-epithelialization except in areas around joints.[8 1]
A group of animals were pre-treated with GCSF subcutaneous injections prior to surgery in order
to increase circulating levels of stem cells through mobilization from the bone marrow. [52] Exogenous
GCSF has not been widely tested in burns, but appears to have positive effects on the immune system
in animal studies and without adverse effects in burn patients.[8 3 1 GCSF may also contribute locally
to the wound healing process, as it has been shown to enhance bone marrow cell differentiation into
vascular endothelium and speed up angiogenesis in a hindlimb-ischemic model.[ 84 ] Though the use
of GCSF in order to release cells from the bone marrow is not a clinically relevant protocol, this
study was designed at the onset to maximize potential therapeutic effects.
Thus, to test the hypotheses related to the goals of this research study, four groups of animals
were selected. Untreated animals grafted with a scaffold serve as the baseline Control group. In
addition, three treated groups grafted with a scaffold of GCSF only (GCSF), a combination of
GCSF and SDF-1 (GCSF+SDF-1) and SDF-1 only (SDF-1) will help elucidate the effect of GCSF
and SDF-1 on wound healing.
4.2 Materials
Male homozygous 29 - 35 day old wild-type mice (C57BL/6) were purchased from Charles River
Laboratories (Wilmington, MA) and maintained in accordance with National Research Council
guidelines. Animal were housed in an AAALAC (Association for Assessment and Accreditation of
Laboratory Animal Care) accredited facility at the Shriners Burns Hospital for Children-Boston.
Recombinant mouse CXCL12/SDF-la was purchased from R&D Systems (Minneapolis, MN).
The 50 jg of SDF-la was diluted in 5 mL of 1X PBS and 100 pL of this solution was administered per
treatment for a dosage of 1 Ag/mouse.[6 7] GCSF was purchased as commercially available Neupogen
(Filgrastim) in 300 MCG/mL concentration from Amgen (Thousand Oaks, CA). The 1 mL of
Filgrastim was diluted in 9 mL of 0.9% saline (Baxter Healthcare, Deerfield, IL) solution. For 300
Ag/kg GCSF dosage per animal, 200 iL of the solution was administered per animal.[52 ]
The 1 mm thick Collagen-GAG (matrix of bovine collagen and chondroitin-6-sulfate, a shark-
derived glycosaminoglycan) dermal scaffold was manufactured in-house to match the thickness of
murine skin using collagen obtained from Integra Life Sciences (Appendix B). Apart from differences
in the pore structure (pores are of uniform size), porosity (top surface of scaffold has less porosity)
and cross-linking method (dehydrothermal instead of glutaraldehyde treatment), it is similar to the
commercially available IntegraTM product used in humans.
4.3 Methods
4.3.1 Experimental Design and Wound Model
All procedures on animals were approved by the Subcommittee on Research Animal Care at the
Massachusetts General Hospital. Mice were housed five animals per cage before surgery or any
treatment and individually caged post wounding in standard microisolator polycarbonate caging.
Animal rooms were maintained at 64 - 79 0 F with 30 - 70% humidity on a 12-hour light/dark cycle.
Commercial rodent ration (LabDiet 5P00 Prolab RMH3000) was provided ad libitum as was acidified
(pH 2.5) water to protect against opportunistic infections.
Wound healing in the animals was examined at an early time-point three days post wounding
(Day 3) and on the day of closure by macroscopic gross appearance (closure day was Day 18).
Figure 4-1: Timeline of Experiment
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Four experimental groups grafted with 1 mm thick collagen-GAG scaffold:
1) Untreated Control group (Day 3: n=6; Day 18: n=4) - Saline s.c. + 1X PBS
locally on the scaffold
2) GCSF group (Day 3: n=5; Day 18: n=4) -GCSF s.c + 1X PBS locally on the
scaffold
3) SDF-1 group (Day 3: n=6; Day 18: n=5) -Saline s.c. + SDF-1 locally on the
scaffold
4) GCSF and SDF-1 (GCSF+SDF-1) group (Day 3: n=6; Day 18: n=4) -GCSF s.c.
+ SDF-1 locally on the scaffold
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The animals were divided in to the following four experimental groups (Figure 4-1):
1. Control group (Day 3: n=6; Day 18: n=4) - The animals were pre-treated with 300 /g/kg
daily subcutaneous saline injections for 5 days prior to surgery. 100 pL of 1X PBS solution
was administered locally on to the wound once a day for 4 days.
2. GCSF group (Day 3: n=5; Day 18: n=4) - The animals were pre-treated with 300 /g/kg
GCSF daily subcutaneous injections for 5 days prior to surgery. 100 IL of 1X PBS solution
was administered locally on to the wound once a day for 4 days.
3. GCSF and SDF-1 (GCSF+SDF-1) group (Day 3: n=6; Day 18: n=4) - The animals were
pre-treated with 300 pg/kg GCSF daily subcutaneous injections for 5 days prior to surgery.
100 IL of SDF-la solution was administered locally on to the wound once a day for 4 days.
4. SDF-1 group (Day 3: n=6; Day 18: n=5) - The animals were pre-treated with 300 /g/kg
daily subcutaneous saline injections for 5 days prior to surgery. 100 pL of SDF-la solution
was administered locally on to the wound once a day for 4 days.
4.3.2 Surgical Procedure and Wound Model
One day prior to surgery, the animals were shaved and depilated (Nair®, Church & Dwight Co.,
Princeton, NJ). On the day of the surgery (Day 0), the mice were weighed and anesthetized with
60 mg/kg Nembutal (Pentobarbital). The dorsal skin was marked with a standardized 1.0 cm2
template. A full-thickness wound was created on the dorsal area of the mouse by excising a 1
cm X 1 cm square of skin (epidermis, dermis and panniculus carnosus). An equivalent piece of
Collagen-GAG dermal scaffold (skin substitute) was grafted on to the wound ensuring that its porous
bottom surface was in contact with the wound bed. After grafting the wound, 100 fLL SDF-1 was
administered on top of the scaffold for the SDF-1 and GCSF+SDF-1 groups. The Control and GCSF
groups received an equivalent amount of 1X PBS solution. Benzoin Tincture Compound (Paddock
Laboratories, Minneapolis, MN) was applied around the wound margins. Once dry, the wound area
was covered with a semi-occlusive polyurethane dressing (TegadermTM , 3M, St. Paul, MN). This
thin, transparent dressing transmits oxygen but prevents excessive evaporation. The subsequent 100
pL SDF-1 or 1X PBS solution treatments were given once a day for 3 additional days by injecting
the solution on top of the scaffold without disturbing the Tegaderm dressing. (Figure 4-2)
Figure 4-2: Wound Model and Surgical Procedure
Three days post surgery, animals from the Day 3 group were euthanized via Isoflurane inhalation
(Isoflurane, USP, NOVAPLUS, Lake Forest, IL, USA) and the wounds were prepared for histological
examination. The rest of the animals were monitored daily till re-epithelialization was observed
macroscopically in the SDF-1, GCSF and GCSF+SDF-1 groups on Day 18 ± 5 hours and then
sacrificed. The wounds were harvested en block including the surrounding skin and underlying
tissue areas. Wound tissues were fixed in 10% neutral-buffered formalin solution for 24 hours and
then stored in 70% alcohol at 40 C.
Wounds were digitally photographed with a Canon PowerShot Prol 8.0 megapixels camera from
a standard height using an Aurich tripod on the day of surgery (Day 0) prior to application of the
Tegaderm dressing and the day the animals were sacrificed (Day 3 and Day 18).
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4.4 Histological and Morphometrical Analysis
Central wound cross-sections were embedded in paraffin, sectioned in to 5 pm sections and stained
according to standard Hematoxylin and Eosin (H&E), Masson's Trichrome and immunohistochem-
istry (PECAM-1, Ki67, a-SMA) protocols. The histological images were photographed using a Nikon
Labophot (Japan) microscope equipped with a Polaroid DMC2 color camera (Concord, MA) with
analysis software version v2.1. In order to ensure consistency in the comparison of the histological
sections, all images were taken from the same area of the histological slide and compared to their
respective H&E images of 10X magnification.
Lateral wound margins in the histological sections were determined by the presence of appendages
(hair follicles, sweat glands) and an organized epidermis and dermis. The healed wound area on Day
18 in comparison had fewer or no appendages and an altered epidermal and dermal structure.[ 8 5]
In the early time-point Day 3 histological sections, the grafted scaffold was clearly evident in the
wound bed. [4 71
4.4.1 Macroscopic Wound Closure Analysis
The initial wound size on Day 0 and the final wound size of the re-epithelialized wound (Day 18)
were measured from the digital macroscopic wound photographs. For quantification of the wound
area, the raw digital files were imported into NIH ImageJ software vl.40g (Image J, NIH, Bethesda,
MD) for processing. Planimetry was used to calculate the scar area by comparing wound contraction
as a percentage of the initial wound area.[851 Macroscopically, the borders of the wound area was
defined by the dermal edges enclosing a region without hair growth. (Figure 4-3 and Figure 4-4).
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Figure 4-3: Stylized Illustration of Parameters of Wound Analysis
Figure 4-4: Macroscopic Quantification of Wound Area
4.4.2 Tissue Morphology
H&E stain was performed to visualize and compare the wound morphology of the early time point
(Day 3) and re-epithelialized wound (Day 18) among animal groups.[86] Images were taken in the
center of each histological section at 4X, 10X and 40X magnifications for both Day 3 and Day 18
animal groups. The digital images at 40X magnification were taken in the center of the wound
scaffold area. The 4X magnification helped maximize the wound closure area being photographed.
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Figure 4-5: Microscopic Quantification of Wound Area
4.4.3 Collagen Analysis
After deparaffinization and rehydration, central wound sections from the Day 18 animal group were
stained with Masson's Trichrome to visualize collagen fibers in the wound bed and surrounding tissue
area of the various animal groups. Digital images of the Masson's Trichrome stained histological
sections were taken at 4X, 10X and 40X magnifications for each slide. The Neoepidermal Length
(NL) and Contraction Distance (CD) were measured using planimetry after processing the digital
images via NIH ImageJ v1.40g software. The Neoepidermal Length defines the distance of re-
epithelialization between the edges of a distinct multi-layer neoepidermis. Contraction Distance
was defined as the distance between the panniculus carnosus in the uninjured normal dermis to the
junction between the normal epidermis and the neoepidermis (Figure 4-5). CD was measured on
both lateral aspects of the wound and averaged.
The maturation of collagen fibers was investigated using polarized light in Masson's Trichrome
stained wound sections, where the tissue specimens were viewed through polarizing filters oriented
at 900.[47] Polarized light microscopy images were taken in the center of the wound area of each
histological section at 10X magnification. In addition, 10X magnification images of the normal
dermis in each histological section were also taken for comparison.
4.4.4 Immunohistochemistry Procedure:
Cell Proliferation and Endothelial Cell Markers
The paraffin-embedded central wound sections from the Day 3 animal group were rehydrated using
a decreasing alcohol chain and stained for cell proliferation (Ki67) and endothelial cell (PECAM-1)
markers according to standard protocols (Appendix A).[ 8 6] The tissue sections stained with the
primary antibodies, PECAM-1 (Pharmingen, San Jose, CA) and Ki67 (LabVision, Freemont, Ca),
were incubated at 40 C overnight. The tissue sections for endothelial cell markers were treated with 40
jpg/mL Proteinase K (Roche Diagnostics Corp., Indianapolis, IN)) for 20 minutes at 370C. Antigen
retrieval for the Ki67 cell proliferation marker was accomplished by microwaving in 10 mM sodium
citrate (pH 6.0) for 10 minutes. Signals were then intensified using a tyramide amplification system
(PerkinElmer, Boston, MA).
4.4.5 Quantification of Cell Proliferation Rate
The cell proliferation rate in Day 3 wound tissue of the various animal groups was analyzed using
the Ki67 stain.[8 6] High-power 40X magnification digital images of Ki67 stained wound sections
were used to measure the number of Ki67 positive cells (brown nuclei) relative to the total number
of nuclei present in the center of the wound scaffold area of each histological section. The cell
proliferation rate was quantified over the entire wound section using 3 fields per histological section
(one in the middle of the granulation tissue and two on either lateral aspect) and expressed as a
percentage of proliferating nuclei (Ki67 positive) to total nuclei. The cell proliferation results of the
various animal groups were then plotted together and statistical analysis was performed.
4.4.6 Quantification of Blood Vessels
The capillary and blood vessel densities in Day 3 wound tissue from the various animal groups
were analyzed using the PECAM-1 (CD31) stain.[86 ] The endothelial cell density was evaluated by
assessing 3 fields per histological stained slide (one in the middle of the wound scaffold area and
two on either lateral aspect) at 40X magnification. Blood vessels (CD31 positive brown nuclei) in
each high-powered field image were counted using Adobe Photoshop CS software (Adobe Systems
Incorporated, San Jose, CA). Only those histological slides that did not exhibit excessive background
staining were considered. The mean values of the results were graphed and statistical analysis was
performed.
4.4.7 Immunohistochemistry Procedure: Myofibroblast Cell marker
Histological slides from the Day 18 animal group were analyzed for the presence of a-smooth muscle
actin (a-SMA) expressing myofibroblast cells using a standard staining protocol.[871 Briefly, the
deparaffinized histological slides were treated with 0.1% trypsin (Sigma Chemical Co., St. Louis,
MO) to facilitate antibody penetration for 1 hour at room temperature. Endogenous peroxidase was
quenched with 3% hydrogen peroxide (Sigma). Nonspecific sites were blocked with 1% goat serum
(Sigma) for 30 minutes. The slides were then incubated at room temperature with anti-a-SMA
(Clone 1A4, Monoclonal, Sigma Chemical Co., St. Louis, MO) at 1:400 dilution for 1 hour. Next,
the slides were incubated with biotinylated goat anti-mouse IgG secondary antibody (Sigma) for 30
minutes followed by 15 minutes of incubation with affinity-purified avidin (Sigma). The labeling
was done with the use of the aminoethyl carbazole (AEC) chromogen kit (Zymed Laboratories Inc.,
South San Francisco, CA) for 10 minutes. Counterstaining with Mayer's hematoxylin for 5 minutes
was followed by a tap water wash and the application of coverslips with glycerol gelatin. Negative
controls of each histological section were also performed, which were stained with Myeloma IgG 2,
instead of the primary antibody.
4.4.8 Quantification of Myofibroblast Cells
The myofibroblast cell densities in Day 18 wound tissue of the various animal groups were analyzed
using the a-SMA stain.18 7 1 Cells were identified as SMA-positive if they displayed the reddish-brown
color for the chromogen used in the a-SMA staining and the intensity of their color was comparable to
that of the smooth muscle cells present in the walls of blood vessels. Digital images of the histological
wound sections at 4X magnification were used to measure the relative percentage of a SMA-positive
cell area in the total wound tissue area via the NIH ImageJ software v1.40g and planimetry. Due to
the high a SMA-positive cell density and the overlap of the cells in the histological sections, the area
of a SMA-positive cells was calculated as there was difficulty in accurately determining the number
of individual cells present. The results were graphed and statistical analysis was performed.
4.4.9 Statistical Analysis
Results are expressed as mean I standard deviation. Independent Student's t-test (two-tailed)
analysis was used to evaluate significant differences between two treatment groups. A p-value <0.05
was considered significant.
Chapter 5
Results
5.1 Modulation of Wound Healing Kinetics
In this study, changes in wound-healing kinetics (contraction and re-epithelialization) were com-
pared between the SDF-1 treated group, GCSF treated group, GCSF+SDF-1 treated group and the
Control group (un-treated wounds).
5.1.1 Macroscopic Wound Closure Analysis
The wounds were followed macroscopically post-surgery (Day 0) until wound closure (re-epithelialization)
was observed. [8 5] By macroscopic observation, when the gross surface of the wound area exhibited a
similar appearance as that of the surrounding un-wounded normal skin region with no redness being
evident, it was determined that wound closure (re-epithelialization) had occurred. By Day 18 all
the groups except the Control group had closed and a marked decrease in the wound surface area
was observed (p < 0.005) (Figure 5-1, Appendix K).
(a) Control (b) GCSF
(d) SDF-1
Figure 5-1: Macroscopic Photos of Study Groups (Day 18 post-surgery)
which is mainly attributable to differences in contraction rate. Macroscopic wound closure was
quantified using digital photographs of the wound area taken on Day 0 and Day 18 of the study.
The scar tissue area was quantified as a percentage of the initial wound area.
Wound Closure (Re-epithelialization) Rate
The SDF-1 treated group exhibited the fastest wound closure of all groups and re-epithelialization
was observed by Day 16 ± 5 hours post-surgery. The GCSF+SDF-1 treated group demonstrated
faster wound closure as compared to the GCSF and Control groups and re-epithelialization was
observed by Day 17 ± 5 hours post-surgery. The GCSF group exhibited the slowest wound closure
among all the treated groups and re-epithelialization was observed by Day 18 ± 5 hours post-surgery.
The wounds in the Control group were not re-epithelialized by gross macroscopic observation on
(c) GCSF+SDF-1
Day 18 and closed only by Day 25 ± 5 hours.
Wound Contraction Rate
By Day 18, the SDF-1 closed wounds were 8.86±0.85% of their initial wound area (Day 0) and showed
a significant inhibition of wound contraction when compared to all other study groups (p < 0.002).
The GCSF+SDF-1 closed wounds were 3.34 ± 0.48% of their initial wound area (Day 0) and showed
a significantly greater contraction as compared to the SDF-1 and Control groups (p < 0.0001), but
less contraction as compared to the GCSF group (p < 0.0004). The GCSF wounds closed by stellate
scar formation and were 0.98 ± 0.27% of their initial wound area (Day 0), demonstrating the most
contraction amongst all the study groups (p < 0.0004). The wounds in the Control group had
not closed by gross macroscopic observation on Day 18 and they were 6.53 ± 0.59% of their initial
wound area (Day 0). The Control wounds showed a significant inhibition of contraction only when
compared to the GCSF and GCSF+SDF-1 treated groups (p < 0.0004) (Figure 5-2).
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Figure 5-2: Macroscopic Analysis of Scar Area (%) (Day 18 post-surgery)
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Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 6.532 0.989 3.342 8.862
Standard Deviation 0.591 0.277 0.486 0.859
Table 5.1: Scar Area (%)
p-value Group comparison types ttest value
Control versus SDF-1 0.00202
Control versus GCSF+SDF-1 0.000195
p < 0.05 is significant Control versus GCSF 0.0000450
GCSF versus GCSF+SDF-1 0.000497
GCSF versus SDF-1 0.699E - 5
SDF-1 versus GCSF+SDF-1 1.089E - 5
Table 5.2: Scar Area Analysis
5.1.2 Results of Macroscopic Wound Closure Analysis
The SDF-1 treated group exhibited the fastest rate of wound closure (re-epithelialization) and the
most significant inhibition of wound contraction. When compared to the Control group, the SDF-1
group exhibited faster wound closure by 36%.
5.1.3 Microscopic (Histological) Wound Closure Analysis
Wound tissue for histological assessment by Masson's Trichrome stain was collected on Day 18
when all the animals in the treated groups had achieved wound closure by re-epithelialization and
digital images of the Masson's Trichrome stained histological sections were taken at 4X magnification
for each slide (Appendix G). The lateral margins of the neoepidermis were distinguishable from
the surrounding normal uninjured epidermis by its "smoothened" appearance and by its lack of
appendages (hair follicles, sweat glands).18 51,[2 71 The Neoepidermal Length (NL) microscopically
measures the distance of re-epithelialization between the edges of a distinct multi-layer neoepidermis.
Contraction Distance (CD) microscopically measures the distance between the panniculus carnosus
in the uninjured normal dermis to the junction between the normal epidermis and the neoepidermis
(Figure 4-5). The wound contraction rate, which is a reduction in the wound size by a centripetal
movement of skin from the margins of the defect, correlates with the Neoepidermal Length and the
Contraction Distance. Thus, the greater the Neoepidermal Length and the lesser the Contraction
Distance, the more wound contraction is inhibited.
Neoepidermal Length
By Day 18, the Neoepidermal Lengths of the SDF-1, GCSF+SDF-1 and GCSF closed wounds were
3.36 ± 1.2 mm, 3.04 ± 0.9 mm and 2.1 ± 0.74 mm respectively. Of all the wounds in the Control
group, only one had re-epithelialized by Day 18 and the Neoepidermal Length of the wounds was
1 ± 0.8 mm. There was a significant difference in Neoepidermal Lengths between the un-treated
Control group and the treated SDF-1 and GCSF+SDF-1 groups (p < 0.01). However, there was
no statistically significant difference observed between the Control and GCSF groups (p < 0.09), or
amongst the treated groups (p < 0.6) (Figure 5-3).
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Figure 5-3: Microscopic Analysis of Neoepidermal Length (mm) (Day 18 post-surgery)
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Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 1.009 2.104 3.048 3.369
Standard Deviation 0.829 0.740 0.900 1.232
Table 5.3: Neoepidermal (Re-epithelialization) Length (mm)
p-value Group comparison types ttest value
Control versus SDF-1 0.011
Control versus GCSF+SDF-1 0.015
p < 0.05 is significant Control versus GCSF 0.096
GCSF versus GCSF+SDF-1 0.158
GCSF versus SDF-1 0.100
SDF-1 versus GCSF+SDF-1 0.665
Table 5.4: Neoepidermal Length Analysis
Wound Contraction Distance
By Day 18, the SDF-1 closed wounds had contracted the least (3.17 ± 0.94 mm) and exhibited
a significant inhibition of wound contraction when compared to the Control and GCSF groups
(p < 0.001). However, there was no statistically significant difference in Contraction Distance
between the SDF-1 and GCSF+SDF-1 groups (p < 0.16). The GCSF+SDF-1 closed wounds had
contracted by 5.47 ± 2.53 mm, which was not significantly different from the other study groups
(p < 0.7). The GCSF closed wounds had contracted by 6.24 ± 0.8 mm, and showed a significantly
higher Contraction Distance than the SDF-1 group (p < 0.001) but not the Control or GCSF+SDF-1
groups (p < 0.59). The wounds in the Control group had contracted by 5.99 ± 0.8 mm, which was
significantly more than the SDF-1 group (p < 0.001) but not the GCSF or GCSF+SDF-1 groups
(p < 0.6) (Figure 5-4).
Figure 5-4: Microscopic Analysis of Contraction Distance (mm) (Day 18 post-surgery)
Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 5.993 6.241 5.475 3.178
Standard Deviation 0.807 0.808 2.531 0.945
Table 5.5: Contraction Distance (mm)
p-value Group comparison types ttest value
Control versus SDF-1 0.001
Control versus GCSF-SDF-1 0.718
p < 0.05 is significant Control versus GCSF 0.679
GCSF versus GCSF-SDF-1 0.598
GCSF versus SDF-1 0.001
SDF-1 versus GCSF-SDF-1 0.166
Table 5.6: Contraction Distance Analysis
5.1.4 Results of Microscopic Wound Closure Analysis
The SDF-1 treated group exhibited the most significant inhibition of wound contraction.
5.2 Analysis of Tissue Morphology
In order to compare the wound morphology of both the early time point (Day 3) and closed (re-
epithelialized) wounds (Day 18), H&E stain was performed on the histological sections and digital
images were taken of each slide at 4X, 10X and 40X magnifications.18 6] In the Day 3 wounds, the
Control group showed the maximum cell infiltrate (blue nuclei) qualitatively when compared to the
treated (SDF-1, GCSF+SDF-1 and GCSF) groups. There was no significant difference observed
qualitatively between the treated groups in the amount of cell infiltrate in the wound area. (Figure
5-5, Appendix C).
(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1
Figure 5-5: Cell Infiltration in Study Groups (Day 3 post-surgery)
In the Day 18 wounds, the wound areas were completely epithelialized in all the treated (SDF-1,
GCSF+SDF-1 and GCSF) groups. There was no significant difference observed qualitatively in the
granulation tissue area or re-epithelialized region amongst the treated groups. In the Control group,
only one wound had completely re-epithelialized by Day 18. (Figure 5-6, Appendix D).
(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1
Figure 5-6: Tissue Morphology of Study Groups (Day 18 post-surgery)
5.2.1 Results of the Tissue Morphology Analysis
The treated (SDF-1, GCSF+SDF-1 and GCSF) groups demonstrated less cell infiltrate qualitatively
in the wound area when compared to the Control group in the early time-point (Day 3). Also, all
the wounds in the treated groups had re-epithelialized by Day 18 but not in the Control group.
5.3 Analysis of Quality of Scar Tissue:
Wound Collagen Deposition and Orientation
Another objective of this study was to assess the quality of the scar tissue. Digital images of the
Masson's Trichrome stained histological sections taken at 4X, 10X and 40X magnifications of the
wound area were qualitatively analyzed (Figure 5-7, Appendix E).[4 7]
(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1 (e) Normal Dermis
Figure 5-7: Collagen Morphology in Study Groups and Normal Dermis (Day 18 post-
surgery)
Figure 5-8: Scar Extending in to Normal Dermis
It was apparent that 18 days post-surgery (Day 18), the collagen bundle organization and cell
density in the scar area of all wound groups (treated and un-treated) were not comparable to the
surrounding un-wounded normal skin. The collagen fibers in the normal dermis were mature (darker
blue), more wavy, thicker and inter-woven. In contrast, the collagen fibers in the scar area were
immature (light blue), thinner and aligned in an orderly manner parallel to the epidermis, which
is typical for immature scar tissue. [4 7] Another indication of the collagen bundles being organized
in a parallel fashion was that most of the fibroblast cells in the scar area were oriented parallel to
the epidermis. There was no significant difference observed qualitatively in the collagen deposition
and orientation in the scar area amongst the treated groups (SDF-1, GCSF+SDF-1 and GCSF)
(Figure 5-7). The wound area in the Control group showed significantly less collagen deposition as
compared to the treated groups since the wounds had not completely re-epithelialized. An interesting
observation was noted with regards to the spread and distribution of the scar tissue. In all the study
groups, the underlying scar tissue (light blue immature collagen) extended beyond the wound region
and well in to the normal dermis region, stretching either above or below the panniculus carnosus
in some tissue sections (Figure 5-8).
The histological sections were also examined under polarized light microscopy and digital images
were taken at 10X magnification of the scar area and the surrounding un-wounded normal dermis for
each slide. By qualitative observation, it was evident that the scar collagen of the treated (SDF-1,
GCSF+SDF-1 and GCSF) groups exhibited weak birefringence as compared to the normal dermal
collagen (Figure 5-9, Appendix F). This is indicative of immature scar tissue. [88] Examination of
the scar areas in the treated groups showed that the collagen fibers were slightly more mature in the
middle and lower part of the scar tissue. There was no significant difference observed qualitatively in
the birefringence of the scar collagen amongst the treated groups. The scar collagen in the Control
group exhibited almost no birefringence since the wounds had not completely re-epithelialized.
(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1 (e) Normal Dermis
Figure 5-9: Birefringence of Collagen in Study Groups and Normal Dermis (Day 18
post-surgery)
5.3.1 Results of the Quality of Scar Tissue Analysis
The treated (SDF-1, GCSF+SDF-1 and GCSF) groups demonstrated the typical orderly collagen
deposition and orientation as well as weak birefringence that is indicative of immature scar tissue
when qualitatively compared to the un-wounded normal dermis. Since all the wounds in the Control
group had not re-epithelialized by Day 18, the wound areas exhibited significantly less collagen
deposition and almost no birefringence when compared to the treated groups.
5.4 Analysis of Cell Proliferation in Wound
The number of proliferating cells in the center of the wound scaffold area of each histological sec-
tion was quantified per high-power field (40X magnification) at the early time-point (Day 3 post-
surgery)[8 61 (Figure 5-10, Appendix H).
(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1
Figure 5-10: Cell Proliferation (Ki67-) in Study Groups (Day 3 post-surgery)
There was a statistically significant difference observed in the cell proliferation rate between the
SDF-1 and Control groups (p < 0.04) (Figure 5-11).
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Figure 5-11: Cell Proliferation Rate (%) (Day 3 post-surgery)
Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 57.076 67.257 75.509 69.177
Standard Deviation 11.926 18.207 15.282 14.810
Table 5.7: Cell Proliferation Rate (Ki67+) (%)
p-value Group comparison types ttest value
Control versus SDF-1 0.043
Control versus GCSF+SDF-1 0.151
p < 0.05 is significant Control versus GCSF 0.320
GCSF versus GCSF+SDF-1 0.854
GCSF versus SDF-1 0.444
SDF-1 versus GCSF+SDF-1 0.482
Table 5.8: Cell Proliferation Rate Analysis
However, there was no statistical difference observed between any of the other treated (GCSF+SDF-
1 and GCSF) groups and the Control group, or amongst the treated (SDF-1, GCSF+SDF-1 and
GCSF) groups.
5.4.1 Results of the Cell Proliferation in Wound Analysis
A statistical difference in the cell proliferation rate was observed only between the SDF-1 treated
and Control groups in the center of the wound scaffold region 3 days post-surgery.
5.5 Analysis of Wound Vascularity
Wound vascularization was quantified as the number of endothelial cells and blood vessels present
in the center of the wound scaffold region per high-power field (40X magnification) at the early
time-point (Day 3 post-surgery)[8 6] (Figure 5-12, Appendix I).
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Figure 5-12: Endothelial Cell Count (CD31+) in Study Groups (Day 3 post-surgery)
There was no statistically significant difference observed in the endothelial cell density between
all the study groups (Figure 5-13).
Figure 5-13: Wound Vascularity (Day 3 post-surgery)
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Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 5 13.2 25.5 19.166
Standard Deviation 8.148 13.084 22.367 15.237
Table 5.9: Endothelial Cell (CD31+) (Number)
p-value Group comparison types ttest value
Control versus SDF-1 0.081
Control versus GCSF+SDF-1 0.077
p < 0.05 is significant Control versus GCSF 0.265
GCSF versus GCSF+SDF-1 0.288
GCSF versus SDF-1 0.502
SDF-1 versus GCSF+SDF-1 0.580
Table 5.10: Endothelial Cell Analysis
5.5.1 Results of the Wound Vascularity Analysis
No statistically significant difference was observed amongst all the study groups (treated and un-
treated) in the endothelial cell density in the center of the wound scaffold region 3 days post-surgery.
5.6 Analysis of Myofibroblast Activity in Wound
The final objective of this study was to measure the relative percentage of a SMA-positive cells
in the total wound tissue in closed (re-epithelialized) wounds (Day 18 post-surgery) using digital
images of the histological wound sections at 4X magnification[8 7 ] (Figure 5-14, Appendix J).
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(a) Control (b) GCSF (c) GCSF+SDF-1
(d) SDF-1
Figure 5-14: Myofibroblast (a SMA+) Cells in Study Groups (Day 18 post-surgery)
However, the wounds in the Control group were not completely closed (re-epithelialized) on Day
18. The relative percentage of a SMA-positive cells in the SDF-1, GCSF+SDF-1, GCSF and Control
groups were 14.34±5.5%, 13.18±8.38%, 5.15±1.12% and 12.41±13.02% respectively. In the Control
and GCSF+SDF-1 groups, a large variation was observed within the individual group itself which
accounts for the large standard deviation. There was a statistically significant difference between
the GCSF and SDF-1 treated groups only (p < 0.02) in the relative percentage of a SMA-positive
cells. Conversely, no statistical difference was observed amongst the other treated groups (SDF-1
and GCSF+SDF-1), or between the Control and treated (SDF-1, GCSF+SDF-1, GCSF) groups
(Figure 5-15).
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Figure 5-15: Myofibroblast Cell Density (%) (Day 18 post-surgery)
Statistics Control GCSF GCSF+SDF-1 SDF-1
Average 12.416 5.159 13.185 14.347
Standard Deviation 13.025 1.125 8.380 5.514
Table 5.11: Relative a-SMA Area (%)
p-value Comparison of Groups ttest value
Control versus SDF-1 0.654
Control versus GCSF+SDF-1 0.924
p < 0.05 is significant Control versus GCSF 0.346
GCSF versus GCSF+SDF-1 0.150
GCSF versus SDF-1 0.022
SDF-1 versus GCSF+SDF-1 0.820
Table 5.12: Relative a-SMA Area Analysis
Based on the data, it can be determined that the SDF-1 group exhibited the most relative
percentage of a SMA-positive cells in the wound region while the GCSF group exhibited the least
amongst all the treated groups. This interesting observation is also evident in a SMA-stained tissue
sections of the wound area located approximately 2 mm superior to the central wound region. In
addition, it was qualitatively observed that a SMA-positive cells were also present around the hair
follicles in the surrounding un-wounded normal dermis region, with the SDF-1 group showing the
most number of a SMA-positive cells and the GCSF group showing the least amongst the treated
groups. (Figure 5-16) Thus, the data clearly indicates that the SDF-1 and GCSF+SDF-1 treated
groups were undergoing further wound contraction 18 days post-surgery, whereas, the process of
wound contraction in the GCSF treated group was nearly complete.
-I·
(a) SDF-1 (b) SDF-1 (c) Normal
Figure 5-16: Myofibroblast (a SMA+) Cells in Wound and Normal Tissue Regions Su-
perior to Central Wound Region (Day 18 post-surgery)
5.6.1 Results of the Myofibroblast Activity in Wound Analysis
Wounds treated with SDF-1 experienced a comparable delay in wound contraction as the Control
group. In contrast, the GCSF treatment appeared to promote wound contraction.
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Chapter 6
Discussion
6.1 Discussion of Results
Topical application of Stromal cell Derived Factor-1 (SDF-1) in this study induced changes in
wound-healing kinetics (contraction and re-epithelialization) compared to GCSF treated group,
GCSF+SDF-1 treated group and spontaneous healing in un-treated wounds (Control group). A
reproducible 1.0 cm 2 dorsal full-thickness excision wound model in wild-type mice was used to in-
vestigate the wound healing kinetics which was monitored macroscopically and microscopically. The
SDF-1 treated group demonstrated the fastest rates of wound closure and cell proliferation as com-
pared to the un-treated Control group, with re-epithelialization occurring more rapidly by 36%. The
amount of early cell infiltrate in the SDF-1 group was also significantly less when compared to the
Control group, which is indicative of a decreased inflammatory response in the SDF-1 group. Al-
though they experienced the same overall delay in wound contraction as the Control group, wounds
treated with SDF-1 exhibited a significant reduction in wound contraction during the initial heal-
ing process. However, there was no significant difference observed amongst the treated (SDF-1,
GCSF+SDF-1 and GCSF) groups in early wound vascularization or in the quality of the scar tissue
based on collagen deposition and orientation.
On the whole, the observed results were consistent with that reported in literature, demonstrating
a decrease in early inflammatory cell infiltration [7 9 ],[73 ] and increased wound re-epithelialization. [6 7]' [5 6] ,[5 5]
Prior experimental results have demonstrated that a small population of bone marrow-derived stem
cells are present in circulation and that some of these bone marrow-derived endothelial cells con-
tribute to the healing of cutaneous wounds by promoting epithelialization.[8 9 1 In addition, topically
applied bone marrow-derived mesenchymal stem cells also enhanced dermal wound healing by accel-
erating angiogenesis and re-epithelialization.19 0 ] Thus, the observed results of this study support the
hypothesis that SDF-1 can improve skin wound healing by altering the dynamics of recruitment of
CXCR4-expressing cells such as bone marrow-derived mesenchymal stem cells and endothelial cells.
However, additional studies will be needed to determine the number of stem cells and endothelial
cells that have been recruited into the wound site.
An alternative theory has been recently proposed where a study found that blocking endoge-
nous levels of SDF-1 resulted in increased re-epithelialization and decreased eosinophil infiltration
in second-degree dermal burn wounds 5 days post-wounding.[ 5 7] Discrepancies between the re-
epithelialization results may be due to variations in the wound model, handling techniques, method-
ology and experimental model. A key difference is that the dermal burn wound study did not
incorporate the use of scaffolds. Also, a second-degree burn injury model is not comparable to a
full-thickness excision wound model and could yield different results. Furthermore, it is unclear as
to what the long-term effects of blocking SDF-1 would be as complete re-epithelialization of the
burn wounds had not occurred. In order to compare results across different studies, consistency in
experimental methodologies and definitions is required.
6.2 Advantages of the Proposed Approach
The proposed approach for skin wound healing, using the well characterized full-thickness skin
wound experimental model, could be applied to chronic wounds (eg. diabetic or venous ulcers),
acute injuries (eg. burns) and elective surgeries, such as cosmetic procedures, with an estimated
2005 market of $1.6 billion per The Freedonia group.[9 1] Other potential applications include tissues
that exhibit poor or incomplete regeneration after injury. Enhancing the healing of other injured
tissues, such as corneal scarring from corneal ulcers, spinal cord injuries, scarification of hand tendons
and myocardial infarction, would provide enormous clinical benefit. In addition, the reduction of
graft rejection and fibrosis around medical implants, such as stents and orthopedic implants, is
another area which might prove helpful to clinicians.
6.3 Limitations of this Study
It is important to note the limitations of this study. There are known problems associated with the
use of wild-type mice, such as their rapid dorsal hair re-growth rate which posed difficulties with
wound dressing maintenance. It has been reported that maintaining the dressing through the follow
up is crucial to prevent wound contamination.[9 21 The diabetic mouse (db/db) model is commonly
used in dermal wound healing studies as db/db mice exhibit less contraction and a greater degree of
epithelialization, which facilitates observation of the wound healing mechanisms, whereas wild-type
mice heal approximately 90% by contraction.[9 2] However, it was opted to not use mouse models
that exhibit underlying diseases in this study.
Additional difficulties in this study arose from the usage of the Collagen-GAG scaffold. The 1
mm thick scaffold was extremely fragile and susceptible to tearing which posed a significant challenge
during the surgical procedure. Microscopic evaluation also showed non-degraded collagen scaffold
fibers in some of the wounds with giant cells and other inflammatory cells in the scar tissue area.[4 71 In
addition, the scaffold was also prone to infection.[4 5 ] Few studies have used Collagen-GAG scaffolds
similar to IntegraTM in mice. Alternatives such as the AllodermTM acellular dermis, which have
been extensively used in mice studies, could be considered instead.[9 31,[9 4 ]
Another drawback of this study is that the progression of wound healing was not observed over
an extended time-course. Only the early time-point (Day 3) and closure time-point (Day 18) were
evaluated. In order to investigate and further explore the healing mechanisms of the inflammatory
phase, angiogenesis, wound contraction and re-epithelialization (keratinocyte migration), experi-
ments at additional time-points (for example, defect contraction half-life at Day 9) would need to
be conducted.[95 ) Additional studies at later time-points (for example, Day 30) are also required to
analyze the final scar tissue formed along with functional tests to test the tensile strength of the
healed wounds.
6.4 Future Work
Additional studies are necessary to determine the optimal dosage and administration schedule of
SDF-1 to maximize the wound healing benefits. Detailed characterization of the morphological and
histological aspects of the wound healing dynamics (inflammation, angiogenesis, fibroblast migra-
tion, wound contraction, scar formation and re-epithelialization) would provide additional insight in
to the underlying mechanism of action of SDF-1. Stem cell, endothelial progenitor cell and inflam-
matory cell activity can also be investigated, using cell culture, flow cytometry, quantitative (Q)
PCR, Western blotting and immunohistochemistry or immunofluorescence techniques, to study the
chemotactic and fugetactic (repellant) role of SDF-1 during wound healing. The dynamics of this
process in the wound environment is important since the timing of cell recruitment and their subse-
quent differentiation likely determine the specific roles played by the stem cells and endothelial cells
in the wound healing response. To characterize this phenomenon, the recruitment of stem cells and
endothelial cells in a standardized full-thickness excision skin wound would need to be monitored.
It remains to be seen whether the dosage and administration of SDF-1 can support a reduction in
wound contraction recurrence long-term.
Although its half-life in vivo is unknown, SDF-1 can be cleaved and degraded by a wide array of
proteolytic enzymes,[4 8] which may limit the effectiveness of SDF-1 in therapeutic settings. Thus,
the use of new forms of SDF-1 that are resistant to proteolysis should be investigated, as they may
help overcome this potential problem. These experiments would help determine the bioactivity of
SDF-1 in this wound healing model. Although no murine model precisely emulates human wound
healing, the db/db animal model could be considered as an alternative to the wild-type mouse model
as it demonstrates reduced wound contraction and hair growth.[9 21
It would be advantageous to incorporate the best SDF-1 dosage and administration strategy
determined from above into a skin substitute using a controlled drug delivery method (Figure 6-1).
I. Scaffold
Figure 6-1: Proposed Drug Delivery Approach of SDF-1 via a Scaffold
This approach would eliminate the need for repeated manual administration of SDF-1 in to the
wound site, thus resulting in less perturbation of the wound bed. Additional benefits include the
meticulous maintenance of the scaffold and wound dressing along with more stringent control of
infection, which are also important aspects necessary for the standardization of this experimental
protocol. Multiple drug delivery schemes would need to be explored, such as nanoparticles made of
polylactic-co-glycolic acid (PLGA), alternating polyelectrolyte layers and liposomes.[9 6] ,[9 71 In order
to determine the optimal parameters of the delivery vehicle (such as, particle size, concentration of
SDF-1 in the particle and concentration of particles in the scaffold), in vitro experiments testing the
various drug delivery schemes would need to be performed to assess the release kinetics of SDF-1.
For clinically relevant studies, further experiments could extend this work to a porcine model
of wound healing, which is more analogous and to human skin than rodents. The wound healing
process should be characterized macroscopically and microscopically by multiple parameters, each
one reflecting a major stage in the typical wound healing process: homing in of inflammatory cells,
angiogenesis, fibroblast migration, wound contraction, re-epithelialization and scar tissue formation.
Immunohistochemical studies to test for the presence of stem cells (hematopoietic and mesenchy-
mal) and progenitor cells (endothelial) should also be considered. Functional tests to analyze the
tensile strength and mechanical properties of the newly formed tissue in the healed wounds are also
necessary. In addition, the solutions developed may be translated to in vivo therapeutic schemes for
human patients.
Drug released
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6.5 Conclusion
In spite of advances made in the care and management of wounds, the goal of promoting faster healing
with "scar-less" wound resolution remains unchanged. As Dr. Anthony Atala aptly remarked, "In
tissue engineering, everything goes back to scar formation."[9 8] Wound healing is a complicated
biological process requiring the appropriate balance of matrix and growth factors. Apart from
causing physical deformity, adult wound healing in humans unfortunately results in the formation
of fibrotic scar tissue which can hinder function and mobility of the organ.
As with dermal substitutes, the proposed approach of treating the scaffold with SDF-1 has
demonstrated the ability to reduce wound contraction at early time points, which would be useful in
the treatment of wounds in functional areas, such as joints. In addition, this approach also exhibited
a faster rate of wound re-epithelialization as compared to un-treated wounds with the dermal scaffold
alone. These results suggest that the SDF-1 treated-dermal matrix may be a new tool to stimulate
wound closure and quality tissue formation in acute and chronic wounds. This approach would
therefore be applicable to the regeneration of poorly healing tissues, and the development of such
solutions would be of significant benefit to human health.
Appendix A
Immunohistochemistry Protocols for
Cell Proliferation (Ki67) Stain and
Endothelial Cell (CD31) Stain
IMMUNOHISTOCHEMISTRY STAINING - PARAFFIN EMBEDDED SECTIONS
General explanation:
1. To stain paraffin embedded sections, the paraffin material must first be removed and then
the sample must be re-hydrated. Re-hydration also reactivates enzymes that must be blocked
with H202.
2. Prior fixation with formalin has caused many proteins to cross-link preventing accessibility
to surface antigens. These antigens are retrieved using a protease. When trying to detect
an internal antigen, the cell membrane is broken by microwaving samples in a basic citrate
releasing the internal antigen.
3. In order for the primary antibody to bind only to the antigen of interest, the samples are
treated with an unspecific protein-based blocker TNB (that acts like a blanket). Now, the
antigen of interest is marked with its specific primary antibody. This antibody is a highly
specific "rat anti-mouse antibody" made by injecting the mouse antigen into a rat.
4. A biotinlated anti-rat (mouse adsorbed) secondary antibody is then added (super-specific).
The biotin unspecifically binds to negatively-charged molecules.
5. Streptavidin-HRP is then added to amplify the signal. Streptavidin is also negatively-charged
molecule which binds to the Biotin, while HRP is an enzyme. Further amplification is achieved
by adding Biotin, and then again adding S-HRP. Leaving biotin on the sample too long will
cause unspecific binding to other less-negative molecules, reducing the specificity of the signal.
6. Finally, DAB chromagen is added and acts like a substrate for HRP. Positive staining for the
antigen will cause a brown color change (can be instantaneous). If the activated chromagen is
left on the samples too long the background will become brown. Stop the reaction by immersing
slides in dH20 as soon as the positive cells have become brown, and minimal background has
stained.
General Instructions:
1. Each container holds approximately 225-250mL of solution.
2. "wet" chamber: Place wet towels along the bottom of a common slide box. Close lid.
3. 1M PBS: dilute 10M PBS stock solution in dH20 (100ml 10M PBS:1000ml dH20)
4. PBS-Tween: add 0.5ml Tween for every 1L of 1M PBS (Tween is a detergent)
5. Ammonium-H20: dilute 0.5ml Ammonium Hydroxide (Menconi) (Toxic!) in 500 ml tap
water.
6. 1M TRIS pH 8: prepare both 1M HCI Tris (acid) and 1M Base Tris (Basic) solving in d-water
the powder, with a ratio 11 H20: 1 weight in grams of the Formula Weight (FW, found on
the box of the salts). Then mix the two solution adding acid to base until the needed pH is
reached.
7. Citrate...
Items to be placed in ice when not in immediate use:
1. TNB
2. Primary Antibody
3. Secondary Antibody
4. Streptavidin-HRP (light sensitive, wrap in foil!)
5. Biotin
6. DAB dissolved in PBS
Staining instructions:
DAY 1:
1. Warm slides on heat plate (for at least 30'-lh), Temp. between 50- 60 'C
(NEVER > 60 0 C to prevent denaturation!)
1. Label slides with a xylene and Etoh resistant pen or regular lead pencil.
2. Deparrafinize with 2 washes of xylene (5min each)
3. Hydrate slides with an Etoh series, diluting Etoh in ddH20. 100%(2mins)-95% (2mins)-
85%(lmin)-70%(lmin)
4. dH20 rinse 1minute
Immerse in Xylene for 3x, 10 min each
REHYDRATION: immerse in alcohol baths of decreasing concentrations:
(a) (100%, 100%, 90%, 70%, 70%, 50%) for 5min each.
Change the alcohol solution every 2 immersions
1. Wash in PBS: 3 times, 10 min each
2. Immerse slides in [30% H202] solution (diluted in methanol), in dark, for 20mins - methanol
dilution: 25 ml of 30% H202 in 225 ml methanol
3. Wash in PBS for 3 times, 5 mins each
CD-31 / CD45- SURFACE ANTIGEN RETRIVAL
1. Prepare a water bath at 37 'C (start beforehand)
2. Prepare a [0.2M] Tris-H20 solution: dilute 1M Tris (basic pH=8.0) with dH20 lml:5ml (50
ml Tris in 200 ml dH20).
3. Place [0.2M] Tris-H20 solution in water bath to equalize temperature before adding proteinase
and slides.
4. Add 90pl of Proteinase K for every 50ml to Tris H20 solution just before immersion of slides.
5. Places slides in water bath: 20 mins
6. Wash in PBS 3 times, 5mins each
Ki67-- INTERNAL ANTIGEN RETRIVAL
1. Immerse slides in citrate (pH=6. 10mM) and microwave slides until solution begins to boil
(breaking cell membranes to expose antigen).
2. STOP microwave, and allow container to rest for 5-6 minutes.
3. Microwave slides again until solution begins to boil.
4. STOP microwave, and allow to rest until solution reaches room temperature (at least 20
minutes).
5. Wash in PBS 3 times, 5min each
- SPECIFIC ANTIGEN ENHANCING:
1. Chose 1-2 sections per slide to stain. Wipe off other sections.
2. Dry the area around desired sections.
3. Draw a circle around the remaining sections with a marker (green, located in refrigerator)
4. Add 100-150ul TNB (allow to defrost beforehand), to sections and leave in wet chamber for
30mins at room temperature.
5. Shake off the agent
6. replace slides in wet chamber, and pipette the primary antibody (1lil:100 l in TNB for CD31,
1 : 200 for Ki67), approx. 70-80j1 pipetted onto each section
7. leave in fridge overnight at 40 C
DAY 2:
Prepare PBS-Tween solution (as per above instructions)
Wash in PBS-Tween: 3x, 5min each
3. As you place slides in wet chamber, pipet secondary antibody (60- 70Il) onto each section, then
leave 1 hour at room temperature
(a) Biotinlated Secondary Antibody: 1ll antibody:2001l in TNB
4. Wash in PBS-Tween, 3x, 5min each
AMPLIFICATION OF SIGNAL:
1. As you place slides in wet chamber, pipet Streptavidin-HRP (60-701l) onto each section, then
leave 30 min at room temperature
(a) Streptavidin-HRP: 1l:100il in TNB
2. Wash in PBS-Tween, 3x, 5min each
3. Replace slides in wet chamber. Pipette Biotin on slides (1/~1:50/0l in amplification dilutant
located in fridge), approx. 60-70pl pipetted onto each section. Biotin should remain on each
slide for ONLY 4 minutes! Important: Be sure to notice the time as you pipette so that
the Biotin is not left on too long!
4. After the 4 min, place slides in PBS-Tween, and wash 3x, 5 min each.
5. Repeat the amplification with streptavidin-HRP: As you place slides in wet chamber, pipette
Streptavidin-HRP (60-70p1l) onto each section, then leave 30 min at room temperature
6. Wash in PBS-Tween, 3x, 5min each
ACTIVATION:
1. Prepare chromagen agent:
(a) Dissolve 1/2 a tablet of DAB (located in fridge, very toxic) in 5mL PBS
(b) Only activate 2-3 mL of this solution at one time.
i. To activate chromagen, add 1pl 30% H202 per 1 mL DAB/PBS solution.
2. Also have two containers of dH20 prepared.
3. Bring slides (in PBS-Tween chamber), dH20 containers, and activated DAB solution to light
microscope.
4. Place slide on microscope under 10x magnification,
5. Activation is often instantaneous. Therefore, once a few drops (approx 3 drops) of activated
DAB solution (Toxic!) is evenly placed on sections, look under microscope and STOP the
reaction once the positive-staining structures are darkened (brown) by placing slide in dH20.
Important: Waiting too long to STOP reaction will cause the background to stain as well!
COUNTERSTAIN:
1. Fill 1 container with Hematoxylin; make sure there is no layer of film on top (Hematoxylin
can be reused- but after a film starts to form, it should only be used 5 or 6 more times). If
there is a film filter the Hematoxylin (remove the film).
2. Fill another container with tap water.
3. Immerse slides in Hematoxylin for 1 min.
4. Immerse slides in water for a few seconds, change water immediately at least one time.
5. Leave slides in the container with constant water flow (not too strong) for at least 10 min.
6. Fill one container with Ammonium-H20 as per above instructions.
7. After the 10 min in water, dip slides in Ammonium-H20 10 times.
8. Put them back in tap water.
COVERSLIPS:
1. Dehydrate tissue with 70% (1 min) 85% (1 min) 100% (1min) 100% (3mins) make sure slide
labeled area is covered with 100%. There should be no H20 molecules on the slide or labels
of the slides
2. Rinse in Xylene to remove PapPen 2x 5 minutes
3. Cover Slip with Permanent mount. Push air bubbles out from beneath the slide with a pipette
tip (very important: small air bubbles will appear much larger under a microscope!)
4. Place slides on aluminum foil to dry
Appendix B
Protocol for Manufacture of
Collagen-GAG Scaffold
C.1. Collagen-Glycosaminoglycan (CG) Suspension Protocol
SUPPLIES
1. 3.6 gm type I microfibrillar bovine tendon collagen (Integra LifeSciences, Inc., placeCityPlains-
boro, StateNJ); store at 40C.
2. 2991.3 ml distilled, deionized water
3. 8.7 ml Glacial Acetic Acid (Mallinckrodt Chemical Co., placeCityParis, StateKY)
4. 0.32 gm Chondroitin 6-sulfate from shark cartilage (Cat. No. C-4383, Sigma-Aldrich Chemical
Co., placeCitySt. Louis, ,StateMO); store at 40C.
EQUIPMENT
1. Suspension cooling system (Brinkman cooler model RC-2T, Brinkman Co., placeCityWest-
bury, StateNY)
2. Suspension mixer (Ultra Turrax T18 Overhead blender, IKA Works, Inc., placeCityWilming-
ton, StateNC)
3. Peristaltic pump (Manostat Cassette Pump, Cat. No. 75-500-000, placeCityManostat, State-
New York, NY)
PROCEDURE
1. Turn on the cooling system (Brinkman model RC-2T) for the blender (Ultra Turrax T18 Overhead
blender, IKA Works) and allow the mixing chamber to cool to 40 C (-30 minutes).
2. Prepare a 0.05 M acetic acid (HOAc) (pH 3.2) solution: add 8.7 ml HOAc (Glacial Acetic Acid,
Mallinckrodt Chemical Co.) to 2991.3 ml of distilled, deionized water in the chemical fume hood.
This solution has a shelf life of approximately 1 week.
3. Blend 3.6 gm of microfibrillar bovine tendon collagen with 600 ml of 0.05 M acetic acid at 15,000
rpm (Blender Setting: 3.25) for 90 minutes at 40C.
4. Prepare the chondroitin 6-sulfate solution: dissolve 0.32 gm chondroitin 6-sulfate (from shark
cartilage: Cat. No. C-4384, Sigma-Aldrich) in 120 ml of 0.05 M acetic acid.
5. Calibrate the peristaltic pump (Manostat Cassette Pump, Cat. No. 75-500-000) to 120 ml per
15 minutes.
6. Add the 120 ml chondroitin 6-sulfate solution dropwise to the blending collagen dispersion over 15
minutes using the peristaltic pump, while maintaining the blender at 15,000 rpm (Blender Setting:
3.25) and 4°C.
7. Blend the collagen-GAG suspension an additional 90 minutes at 15,000 rpm (Blender Setting:
3.25) at 40 C.
8. Degas the collagen-GAG suspension in a vacuum flask for 60+ minutes until bubbles are no longer
present in the solution.
9. Store the suspension in a capped bottle at 40 C; it will keep for up to four months.
10. If collagen-GAG suspension has been stored for more than one week, re-blend it for fifteen
minutes at 10,000 rpm (Blender Setting: 2) at 40 C and degas again.
C.2. Collagen-GAG Scaffold Fabrication: Constant Cooling Lyophilization Protocol -
Long Version
REFERENCE: (O'Brien, Harley, et al., 2004; O'Brien, Harley, et al., 2005)
SUPPLIES
§ Type I collagen-glycosaminoglycan suspension (67.25 ml/sheet)
§ 5" x 5", 18 gauge 304 stainless steel pan (VirTis Inc., Gardiner, NY)
§ 0.05 M acetic acid
EQUIPMENT
§ Genesis freeze dryer (VirTis)
PROCEDURE
1. Turn on the freeze dryer (VirTis Genesis): Check that the vacuum oil level is at least 2/3, the
oil appears clean, and that the vacuum pump is properly vented (either outside or into a chemical
fume hood).
Plug the condenser drain valve and close the condenser and main chamber door.
Turn the main Power switch on.
Turn the Condenser switch on.
Set the SV gauge to 200C and turn on the Freeze and Heat switches
You need to allow approximately 60 minutes for the freeze dryer temperature to stabilize and for
the condenser to reach a cold enough temperature to continue.
2. Degas the CG suspension in a vacuum flask (Pressure: -50 mTorr). Degas approximately twice
the required volume to allow appropriate removal of all air bubbles. The length of time needed to
degas the suspension varies from 30 - 90 min. depending on the total volume being degassed and
the length of time the entire volume of suspension was degassed immediately following mixing.
3. Clean the stainless steel pan (VirTis) with ethanol or 0.05 M acetic acid and wipe the inside
with Kim-Wipes to remove all dust and any remaining CG content from the previous run. When
cleaning and handling the pan, do not touch the inside of the pan with your bare hands. Use gloves.
Allow the pan to air dry.
4. Pipet 67.25 ml of the degassed CG suspension into each pan.
5. Remove any air bubbles introduced into the suspension during the pipetting step using a 200 pl
pipette tip. Drag the bubbles to the edge of the pan, allowing them to stick to the edge. Place the
pan into the freeze dryer.
6. Check the appropriate program is selected using the Wizard controller. Press the button under
Program X (X = 1 - 12) (Button #1) on the digital display. Select the appropriate program
number using the Up and Down keys and then press the Edit key. Check the program variables
(Temperature, Time, Ramp/Hold) against those detailed below. If the progression is incorrect,
correct the values. Use the outer two buttons to scroll left or right through the program and the
inner two keys to change the value of the selected criteria to match the desired program.
Program 2
Ramp to - - 40 0C. Total time from start to sublimation: -135 minutes
Mean pore size: 95.9 ± 12.3 pm
Percent porosity: 0.994
Specific surface area (S.A./Vol): 0.00748 jm
Freeze dryer program to fabricate CG scaffolds with a 96 pm mean pore size:
Freezing Step Temperature, oC Time, min R/H
1(start) 20 5 H
2("'ramping"') -40 65 R
3("'annealing"') -40 > 60 H
NOTE: In all cases, Step 3 should run for at least 60 minutes, but it is given a longer time in case
you are delayed in returning. It is acceptable for that step to run longer than 60 minutes, since the
solidification process will be complete by that point.
1. After confirming the program, press the two middle keys on the Wizard together to end the
editing step. Select the Save option from the menu displayed after ending the editing step.
The Wizard screen should return to the original screen seen at start-up.
2. Turn off the Freeze and Heat buttons, turn the Auto button on, and press the Start key.
The program should start running. Leave the program to run for the specified length of time.
3. At the end of the 60 minute annealing period, cancel the program. Press the inner two buttons
on the wizard controller together, and then when prompted press the outer two keys. Turn
off the Auto switch, then turn on the Freeze and Heat switches and set the SV to the
appropriate freezing temperature (-10, -20, -30, or -400C).
4. Turn on the Vacuum switch. Make sure the seal on the condenser and main chamber doors
is tight and put pressure on the door to the main chamber until a vacuum pressure registers
on the Wizard control screen (typically ~1900 mTorr).
5. When the vacuum pressure reaches below 300 mTorr, raise the temperature in the SV display
to 0oC. Allow the freeze dryer to run for 17 hours at 0oC and a pressure <300 mTorr.
6. After 17 hours, raise the value of the SV control to 2000C. Wait for the chamber temperature
to equilibrate to 200C (temperature displayed in the PV display). Turn off the Vacuum
switch and turn on the Chamber Release switch. Wait for the pressure to equilibrate to
atmospheric pressure. Remove the pan from the main chamber.
7. Turn off the freeze dryer:
Turn off the Chamber Release switch
Turn off the Freeze and Heat switches
Turn off the Condenser Switch
Turn off the Power Switch
Open the condenser door, unplug the condenser drain line allow condense to drain.
8. Remove the CG scaffold from the pan with gloved hands. Place the scaffold into an aluminum
foil packet and store it in a dessicator.
9. Wash the stainless steel pan with ethanol or 0.05 M acetic acid and wipe down with Kim-Wipes
to remove any portion of the scaffold that may have torn during removal. Return the pan to
storage.
10. Make a notation on the run sheet attached to the front of the freeze dryer in order to keep
track of the total number of runs between oil changes. When a row is completely checked off
(8 freeze dryer runs), change the oil.
C.4. Dehydrothermal Crosslinking Protocol
REFERENCE: (Yannas and Tobolsky, 1967; Yannas, Lee, et al., 1989; Harley, Spilker, et al.,
2004)
EQUIPMENT
§ Isotemp vacuum oven (Model 201, Fisher Scientific, Hanover Park, IL)
PROCEDURE
1. Place the collagen-GAG scaffold into an aluminum foil packet. Leave the packet open at the
top.
2. Select the appropriate processing conditions. The following processing conditions are those
that are typically utilized:
DHT105/24 (Cross-linking temperature: 105 0 C for Cross-linking time: 24 hours) is the accepted
laboratory standard crosslinking technique and is the default crosslinking applied to collagen-GAG
scaffolds unless otherwise noted.
1. Place the packet into vacuum oven (Isotemp Model 201, Fisher Scientific) maintained at the
desired temperature. Open the "Vacuum" knob (turn the knob counterclockwise) and close
the "Purge" knob (turn the knob clockwise).
2. Turn on the vacuum pump. Wait until the vacuum has been obtained (nearly full scale on the
vacuum oven dial).
3. At the end of the processing period, turn off the vacuum and vent the chamber by closing
the "Vacuum" knob (clockwise) and opening the "Purge" knob (counterclockwise). Once the
vacuum has completely vented, open the vacuum oven door and immediately seal the aluminum
foil bag(s). The scaffold is now crosslinked and considered sterile; to maintain sterility, handle
the scaffold from this point on using aseptic techniques.
4. Store the scaffold in a dessicator. Crosslinked scaffolds can remain indefinitely in a dessicator
prior to use.
Appendix C
H&E Stain (Day 3 Post-Surgery)
(a) 4X (b) 10X (c) 40X
Figure C-1: Animal CA3 (Untreated Control Group with scaffold)
(a) 4X (b) 10X
Figure C-2: Animal CB3 (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-3: Animal CC3 (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-4: Animal CD3 (Untreated Control Group with scaffold)
(c) 40X
(a) 4X (b) 10X
Figure C-5: Animal CE3 (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-6: Animal CF3 (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-7: Animal GB3 (GCSF with scaffold)
(c) 40X
(b) 10X (c) 40X
Figure C-8: Animal GC3 (GCSF with scaffold)
(b) 10X (c) 40X
Figure C-9: Animal GD3 (GCSF with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-10: Animal GE3 (GCSF with scaffold)
(a) 4X
(a) 4X
(b) 10X (c) 40X
Figure C-11: Animal GF3 (GCSF with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-12: Animal SA3 (SDF-1 with scaffold)
(b) 10X (c) 40X
Figure C-13: Animal SB3 (SDF-1 with scaffold)
(a) 4X
(a) 4X
(b) 10X (c) 40X
Figure C-14: Animal SC3 (SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-15: Animal SD3 (SDF-1 with scaffold)
(b) 10X (c) 40X
Figure C-16: Animal SE3 (SDF-1 with scaffold)
(a) 4X
(a) 4X
(b) 10X (c) 40X
Figure C-17: Animal SF3 (SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-18: Animal SGA3 (GCSF + SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure C-19: Animal SGB3 (GCSF + SDF-1 with scaffold)
(a) 4X
(a) 4X (b) 10X (c) 40X
Figure C-20: Animal SGC3 (GCSF + SDF-1 with scaffold)
(b) 10X (c) 40X
Figure C-21: Animal SGD3 (GCSF + SDF-1 with scaffold)
(b) 10X (c) 40X
Figure C-22: Animal SGE3 (GCSF + SDF-1 with scaffold)
(a) 4X
(a) 4X
(b) 10X (c) 40X
Figure C-23: Animal SGF3 (GCSF + SDF-1 with scaffold)
(a) 4X
Appendix D
H&E Stain (Day
(a) 4X
18 Post-Surgery)
(b) 10X (c) 40X
Figure D-1: Animal CXA (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-2: Animal CXB (Untreated Control Group with scaffold)
(b) 10X
Figure D-3: Animal CXC (Untreated Control Group with scaffold)
(b) 10X (c) 40X
Figure D-4: Animal CXD (Untreated Control Group with scaffold)
(b) 10X (c) 40X
Figure D-5: Animal GSXA (GCSF + SDF-1 Group with scaffold)
(a) 4X
(a) 4X
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(a) 4X (c) 40X
zoom,
(b) 10X (c) 40X
Figure D-6: Animal GSXB (GCSF + SDF-1 Group with scaffold)
(b) 10X (c) 40X
Figure D-7: Animal GSXC (GCSF + SDF-1 Group with scaffold)
(b) 4X (c) 4X
Figure D-8: Animal GSXD (GCSF + SDF-1 Group with scaffold)
(a) 4X
(a) 4X
(a) 4X
(b) 10X (c) 40X
Figure D-9: Animal GXA (GCSF Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-10: Animal GXB (GCSF Group with scaffold)
(b) 10X (c) 40X
Figure D-11: Animal GXC (GCSF Group with scaffold)
(a) 4X
(a) 4X
'; ;
:
(b) 10X
Figure D-12: Animal GXD (GCSF Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-13: Animal SXA (SDF-1 Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-14: Animal SXB (SDF-1 Group with scaffold)
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(a) 4X (c) 40X
(b) 10X (c) 40X
Figure D-15: Animal SXC (SDF-1 Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-16: Animal SXD (SDF-1 Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure D-17: Animal SXE (SDF-1 Group with scaffold)
(a) 4X
Appendix E
Masson's Trichrome Stain (Day 18
Post-Surgery)
(b) 10X (c) 40X
Figure E-1: Normal Uninjured Dermis Region
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(a) 4X
(b) 10X (c) 40X
Figure E-2: Normal Uninjured Dermis Region
(a) 4X (b) 10X (c) 40X
Figure E-3: Animal CXA (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-4: Animal CXB (Untreated Control Group with scaffold)
(a) 4X
- aflBL~
(a) 4X (b) 10X (c) 40X
Figure E-5: Animal CXC (Untreated Control Group with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-6: Animal CXD (Untreated Control Group with scaffold)
*v't.
(a) 4X (b) 10X (c) 40X
Figure E-7: Animal GSXA (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 10X (c) 40X
Figure E-8: Animal GSXB (GCSF + SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-9: Animal GSXC (GCSF + SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-10: Animal GSXD (GCSF + SDF-1 with scaffold)
105
/(a) 4X (b) 10X
Figure E-11: Animal GXA (GCSF with scaffold)
(b) 10X (c) 40X
Figure E-12: Animal GXB (GCSF with scaffold)
(b) 10X
Figure E-13: Animal GXC (GCSF with scaffold)
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(c) 40X
(a) 4X
(a) 4X (c) 40X
vI
(a) 4X (b) 10X
Figure E-14: Animal GXD (GCSF with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-15: Animal SXA (SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
Figure E-16: Animal SXB (SDF-1 with scaffold)
(c) 40X
(b) 10X (c) 40X
Figure E-17: Animal SXC (SDF-1 with scaffold)
(a) 4X (b) 10X (c) 40X
(d) 40X
Figure E-18: Animal SXD (SDF-1 with scaffold)
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(a) 4X
(a) 4X (b) 10X
Figure E-19: Animal SXE (SDF-1 with scaffold)
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(c) 40X
Appendix F
Polarized Light Microscopy (Day
Post-Surgery)
(a) 10X (b) 10X
Figure F-1: Animal CXA (Untreated Control Group with scaffold)
110
18
(a) 10X (b) 10X
Figure F-2: Animal CXB (Untreated Control Group with scaffold)
(a) 10X (b) 10X
Figure F-3: Animal CXC (Untreated Control Group with scaffold)
(a) 10X (b) 10X
Figure F-4: Animal CXD (Untreated Control Group with scaffold)
(a) 10X (b) 10X
Figure F-5: Animal GSXA (GCSF + SDF-1 with scaffold)
(a) 10X (b) 10X
Figure F-6: Animal GSXB (GCSF + SDF-1 with scaffold)
(a) 10X (b) 10X
Figure F-7: Animal GSXC (GCSF + SDF-1 with scaffold)
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(a) 10X (b) 10X
Figure F-8: Animal GSXD (GCSF + SDF-1 with scaffold)
(a) 10X (b) 10X
Figure F-9: Animal GXA (GCSF with scaffold)
(a) 10X (b) 10X
Figure F-10: Animal GXB (GCSF with scaffold)
(a) 10X (b) 10X
Figure F-11: Animal GXC (GCSF with scaffold)
(a) 10X (b) 10X
Figure F-12: Animal GXD (GCSF with scaffold)
(a) 10X (b) 10X
Figure F-13: Animal SXB (SDF-1 with scaffold)
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(a) 10X (b) 10X
Figure F-14: Animal SXB (SDF-1 with scaffold)
(a) 10X (b) 10X
Figure F-15: Animal SXC (SDF-1 with scaffold)
(a) 10X (b) 10X
Figure F-16: Animal SXD (SDF-1 with scaffold)
(a) O1X (b) 10X
Figure F-17: Animal SXE (SDF-1 with scaffold)
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Appendix G
Masson's Trichrome Stain (Day 18
Post-Surgery
(a) 4X (b) 4X (c) 4X
Figure G-1: Animal CXA (Untreated Control Group with scaffold)
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(a) 4X (b) 4X
(d) 4X
Figure G-2: Animal CXB (Untreated Control Group with scaffold)
(a) 4X (b) 4X (c) 4X
(d) 4X
Figure G-3: Animal CXC (Untreated Control Group with scaffold)
(c) 4X
(a) 4X (b) 4X (c) 4X
Figure G-4: Animal CXD (Untreated Control Group with scaffold)
(a) 4X (b) 4X (c) 4X
(d) 4X
Figure G-5: Animal GSXA (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure G-6: Animal GSXB (GCSF + SDF-1 with scaffold)
(a) 4X (b) 4X (c) 4X
(d) 4X
Figure G-7: Animal GSXC (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 4X (c) 4X
(d) 4X (e) 4X
Figure G-8: Animal GSXD (GCSF + SDF-1 with scaffold)
(a) 4X (b) 4X (c) 4X
Figure G-9: Animal GXA (GCSF with scaffold)
(a) 4X (b) 4X (c) 4X
Figure G-10: Animal GXB (GCSF with scaffold)
,.1F. 4. * ~
AV 10
(a) 4X (b) 4X (c) 4X
(d) 4X
Figure G-11: Animal GXC (GCSF with scaffold)
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(b) 4X (c) 4X
(d) 4X
Figure G-12: Animal GXD (GCSF with scaffold)
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(a) 4X (b) 4X (c) 4X
Figure G-13: Animal SXA (SDF-1 with scaffold)
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(a) 4X
(b) 4X
Figure G-14: Animal SXB (SDF-1 with scaffold)
(a) 4X (b) 4X
Figure G-15: Animal SXC (SDF-1 with scaffold)
(a) 4X (b) 4X
Figure G-16: Animal SXD (SDF-1 with scaffold)
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(a) 4X (c) 4X
AV
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(a) 4X (b) 4X
Figure G-17: Animal SXE (SDF-1 with scaffold)
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(c) 4X
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Appendix H
Ki67 Stain (Day 3 Post-Surgery)
(a) 40X (b) 40X (c) 40X
Figure H-1: Animal CA3 (Untreated Control Group with scaffold)
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(a) 40X (b) 40X
Figure H-2: Animal CB3 (Untreated Control Group with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-3: Animal CC3 (Untreated Control Group with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-4: Animal CD3 (Untreated Control Group with scaffold)
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(c) 40X
(a) 40X (b) 40X
Figure H-5: Animal CE3 (Untreated Control Group with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-6: Animal CF3 (Untreated Control Group with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-7: Animal GB3 (GCSF with scaffold)
(c) 40X
(b) 40X (c) 40X
Figure H-8: Animal GC3 (GCSF with scaffold)
(b) 40X
Figure H-9: Animal GD3 (GCSF with scaffold)
(a) 40X (b) 40X
(c) 40X
(c) 40X
Figure H-10: Animal GE3 (GCSF with scaffold)
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(a) 40X
(a) 40X
(a) 40X (b) 40X
Figure H-11: Animal GF3 (GCSF with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-12: Animal SA3 (SDF-1 with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-13: Animal SB3 (SDF-1 with scaffold)
(c) 40X
(a) 40X (b) 40X
Figure H-14: Animal SC3 (SDF-1 with scaffold)
(b) 40X (c) 40X
Figure H-15: Animal SD3 (SDF-1 with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-16: Animal SE3 (SDF-1 with scaffold)
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(a) 40X
(c) 40X
(a) 40X (b) 40X (c) 40X
Figure H-17: Animal SF3 (SDF-1 with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-18: Animal SGA3 (GCSF + SDF-1 with scaffold)
133

(b) 40X (c) 40X
Figure H-21: Animal SGD3 (GCSF + SDF-1 with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-22: Animal SGE3 (GCSF + SDF-1 with scaffold)
(a) 40X (b) 40X (c) 40X
Figure H-23: Animal SGF3 (GCSF + SDF-1 with scaffold)
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Appendix I
CD31 Stain (Day 3 Post Surgery
(a) 40X (b) 40X (c) 40X
Figure I-1: Animal CD3 (Untreated Control Group with scaffold)
(a) 40X (b) 40X
Figure 1-2: Animal CE3 (Untreated Control Group with scaffold)
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(c) 40X
Figure 1-3: Animal CF3 (Untreated Control Group with scaffold)
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(a) 40X (b) 40X
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(C) 40X
Figure 1-4: Animal GB3 (GCSF with scaffold)
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(a) 40X (b) 40X
Figure I-5: Animal GD3 (GCSF with scaffold)
(a) 40X (b) 40X
Figure I-6: Animal GF3 (GCSF with scaffold)
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(a) 40X (b) 40X
Figure 1-7: Animal SB3 (SDF-1 with scaffold)
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(c) 40X
(c) 40X
(c) 40X
(a) 40X (b) 40X
Figure I-8: Animal SC3 (SDF-1 with scaffold)
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Figure I-9: Animal SD3 (SDF-1 with scaffold)
(a) 40X
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(c) 40X
Figure 1-10: Animal SE3 (SDF-1 with scaffold)
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(c) 40X
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(a) 40X (b) 40X (c) 40X
Figure I-11: Animal SF3 (SDF-1 with scaffold)
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(a) 40X (b) 40X (c) 40X
Figure 1-12: Animal SGA3 (GCSF + SDF-1 with scaffold)
5'd
:;P·
.; Ur
(a) 40X (b) 40X
Figure 1-13: Animal SGB3 (GCSF + SDF-1 with scaffold)
(c) 40X
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(a) 40X (b) 40X
Figure 1-14: Animal SGC3 (GCSF + SDF-1 with scaffold)
(a) 440X (b) 40X (4
Figure 1-15: Animal SGE3 (GCSF + SDF-1 with scaffold)
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(b) 40X
Figure 1-16: Animal SGF3 (GCSF + SDF-1 with scaffold)
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c) 40X
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(c) 40X
(c) 40X
e eft C31 clls ddle CD31 cl R 0i C 31+ c
CA3 0 0 0
CB3 1 0 1 0 1 0
CC3 0 0 0
CD3 4 1 2 1 3
SB3 13 10 7
S3 5 11 | 8
SGA3 11 10 16
SGB3 15 24 23
Standard Dviatonm
CONTROL GCSF SDF-1 SDF-1+GCSF between the
groups
Blood vessels apparent
CD31+ Cell Count
Control CS SDi-l1 SDF10-b
Sd A t 8 1 19515 1 13.24 1 19.1666712 256971 StandardDeviation 1 8.148619515 1 13.08434179 115.237021 22.36738697
30
24
37
19 16666667
RESULTS
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Appendix J
a-SMA Stain (Day 18 Post-Surgery)
(a) 4X (b) 4X
Figure J-1: Animal CXA (Untreated Control Group with scaffold)
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(a) 4X (b) 4X
Figure J-2: Animal CXB (Untreated Control Group with scaffold)
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Figure J-3: Animal CXC (Untreated Control Group with scaffold)
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(a) 4X
S
(b) 4X
Figure J-4: Animal CXC (Untreated Control Group with scaffold)
(a) 4X (b) 4X
Figure J-5: Animal GSXA (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure J-6: Animal GSXB (GCSF + SDF-1 with scaffold)
(a) 4X (b) 4X
Figure J-7: Animal GSXC (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure J-8: Animal GSXD (GCSF + SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure J-9: Animal GXA (GCSF with scaffold)
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(a) 4X (b) 4X
Figure J-10: Animal GXB (GCSF with scaffold)
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(a) 4X (b) 4X
Figure J-11: Animal GXC (GCSF with scaffold)
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(a) 4X (b) 4X
Figure J-12: Animal GXD (GCSF with scaffold)
(a) 4X (b) 4X
Figure J-13: Animal SXA (SDF-1 with scaffold)
(a) 4X (b) 4X
Figure J-14: Animal SXB (SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure J-15: Animal SXC (SDF-1 with scaffold)
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(a) 4X (b) 4X
Figure J-16: Animal SXD (SDF-1 with scaffold)
(a) 4X (b) 4X
Figure J-17: Animal SXE (SDF-1 with scaffold)
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Appendix K
Gross Macroscopic pictures of Wound
Tissue (Day 18 Post-Surgery)
(a) Animal CXA (b) Animal CXB
Figure K-1: Untreated Control Group with scaffold
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(a) Animal CXC (b) Animal CXD
Figure K-2: Untreated Control Group with scaffold
(a) Animal GSXA (b) Animal GSXB
Figure K-3: GCSF + SDF-1 Group with scaffold
(a) Animal GSXC (b) Animal GSXD
Figure K-4: GCSF + SDF-1 Group with scaffold
(a) Animal SXA (b) Animal SXB
Figure K-5: SDF-1 Group with scaffold
(a) Animal SXC (b) Animal SXD (c) Animal SXE
Figure K-6: SDF-1 Group with scaffold
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